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INTRODUCTION 
 Dengue infection is one of the commonest mosquito borne acute febrile viral 
haemorrhagic illness. Dengue epidemics were reported throughout the world, but most 
frequently from the region of South Asia. Most of the studies regarding Dengue infection/virus, 
epidemiological, Clinical and management pattern were studied in the region of South Asia. 
 
 Dengue infection presents with varied clinical manifestation ranging from asymptomatic 
or simple viral illness to circulatory shock (DSS). Dengue infection has the potential to cause 
severe bleeding, shock and death. So, early diagnosis and recognition of complication is 
cornerstone in management. Even though, Dengue infection admissions are common in pediatric 
age group, adult patients admissions has also increased in recent years. However, the datas of 
Dengue infection among adults are limited. This study is to get additional datas on Dengue 
infection among adults from Chennai, which is from the region of South Asia. 
 
 This study is done in Stanley Medical College, North Chennai which is highly endemic 
for communicable infectious diseases. This study deals with Clinical and Laboratory profile of 
Dengue infection among adults from North Chennai. 
 
 
 
  
 
 
AIM OF THE STUDY 
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AIM OF THE STUDY 
 To study the Clinical profile of Dengue Infection among age of >13yrs in the North 
Chennai, attending Medical Department, Govt. Stanley Hospital. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
Dengue fever (DF) is a mosquito borne acute febrile viral disease frequently presenting 
with headaches, bone or joint and muscular pains, rash and leukopenia. Dengue hemorrhagic 
fever (DHF) is characterized by four major clinical manifestations: Fever, Thrombocytopenia, 
Hemorrhagic phenomena and Plasma leakage manifestations. If DHF associated with circulatory 
shock is called Dengue Shock Syndrome (DSS). 
EPIDEMIOLOGY 
During the 19th century, dengue was considered a sporadic disease, causing epidemics at 
long intervals. However, dramatic changes in this pattern have occurred and currently, dengue 
ranks as the most important mosquito borne viral disease in the world. In the past 50 years, its 
incidence has increased 30-fold with significant outbreaks occurring in five of six World Health 
Organisation (WHO) regions. At present, dengue is endemic in 112 countries in the world2.  
Around 2.5 to 3 billion people, living mainly in urban areas of tropical and subtropical 
regions, are estimated to be at risk of acquiring dengue viral infections. Estimates suggest that 
annually 100 million cases of dengue fever and half a million cases of dengue haemorrhagic 
fever(DHF) occur in the world with a case fatality in Asian countries of 0.5%–3.5%.Of those 
with DHF, 90% are children less than 15 years of age5. 
The disease was first recognized in the Philippines in 1953. This gradually spread to 
other countries in the region. Major epidemics occurred in other regions of the world in the 
1980s and 1990s and were caused by all four dengue viral serotypes. While the predominant 
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serotype in the 1980s and the early 1990s was DEN-2, in recent years it has changed to the DEN-
3 serotype. In 1998, a pandemic of dengue viral infection occurred, when 1.2 million cases of 
dengue fever and DHF were reported from 56 countries worldwide. The world population was 
exposed to a new subtype of the DEN-3 virus (subtype III), which originated in the Indian 
subcontinent and later spread to involve other continents. Exposure of a non-immune population 
to this new subtype of DEN-3 may have been the cause of this pandemic5.   
Worldwide dengue distribution – 20062  
(Red: Epidemic dengue. Blue:Aedes aegypti.) 
EPIDEMIOLOGICAL TRENDS IN SOUTH EAST ASIA3,6 
 The first epidemic of DHF in South East Asia occurred in 1954 in Manila, Philippines. 
Following this, epidemics have occurred in nearly all countries in this region. Although 
serological surveys conducted in Indonesia showed that DEN-1 and DEN-2 were the prevalent 
serotypes until the late 1980s, the DEN-3 serotype has been the predominant serotype in the  
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recent outbreaks. DEN-3 has been associated with severe dengue epidemics10. Although DEN–4 
has been isolated in almost all epidemics, it is primarily detected in secondary dengue infections. 
In 2003 only 8 countries in South East Asia Region reported dengue cases. As of 2006, ten out of 
the eleven countries in the Region6 (Bangladesh, Bhutan, India, Indonesia, Maldives, Myanmar, 
Nepal, SriLanka, Thailand and Timor-Leste) reported dengue cases. Bhutan reported the first 
dengue outbreak in 2004. An outbreak, with a high case fatality rate (3.55%) was first reported 
in Timor-Leste in 20057. Nepal reported dengue cases for the first time in November 2006. The 
Democratic Peoples’Republic of Korea is the only country in this Region of WHO that has no 
report of indigenous transmission of DF/DHF5. 
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EPIDEMIOLOGICAL TRENDS IN INDIA 
 Dengue fever was first reported in 1963 from Calcutta city. Since then several outbreaks 
of dengue fever was reported from India with a major epidemic of dengue haemorrhagic fever 
that occurred in Delhi in 1996 when 10,252cases and 423 deaths were reported. Cases have been 
reported from the neighboring states of Haryana, Punjab, Rajasthan, Utter Pradesh and two 
southern and western states. DEN-2 was isolated during this epidemic and the proportion of DHF 
to DF was very high. The number of DF/DHF cases and deaths reported since the epidemic has  
been low till 2002 but again  has risen in 200339. In 2005, both the reported dengue cases and 
deaths show threefold increase as compared to 2004. The case fatality has been above 1% for the 
last 10 years7.  However, the number of reported dengue cases and deaths   are mainly from the 
capital city Delhi and the other states that have small outbreaks go unreported. Therefore the case 
surveillance needs further strengthening. 
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Aedes aegypti was reported from all the affected areas with house indices exceeding 
20%. Surveillance activities are carried out on a limited scale by the National Institute of 
Virology, Pune and few other institutions in the country.  Since 199616, dengue control activities 
are coordinated and carried out by the National Anti-Malaria Programme. 
In 2006 the number of cases reported as compared to 2005 shows some reduction 
whereas the Case fatality rate has remained above 1%. 
 
During 2007(upto 19 June), 383 cases and 6 deaths have been reported from Kerala (188 
cases); Gujarat (93); Maharastra(15); Tamil Nadu(41); Karnataka(27); Haryana(5); Delhi (4); 
Rajasthan (4), Orissa (4), Chandigarh (1) and Uttar Pradesh (1).  
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The trend data from India shows that cases generally start to increase from august 
onwards, which is post monsoon season. More importantly, it is clear from data that breeding 
of Aedes mosquitoes however begins in June itself.  Such data may be taken into consideration  
,  
 while planning in advance for dengue prevention and control. Thus vector surveillance and 
control measures supported by community mobilization for behavioural change activites need to 
be taken before June and sustained throughout the rainy season. 
 
In Tamil Nadu, there has been an increase in the number of dengue cases reporting units 
during the last nine years. In 1998, dengue cases were reported from only 4 units which 
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increased to 33 units in 2006 due to the availability of serodiagnostic facilities at different 
centres in the State. Of the 30 districts in Tamil Nadu, dengue cases have been reported from 29 
districts  
 
between 1998 and 2005 which include DF/DHF outbreaks in Chennai in 200115, Nagercoil and 
Trichirapalli (2003) (unpublished data) and DF outbreaks in Krishnagiri and Dharmapuri 
districts8 in 2001. It is not clearly known why dengue cases have not been reported so far in 
Nilgiris district although the fever surveillance system is well in existence through Primary 
Health Care network. The probable reason could be that Nilgiris is a high altitude area where the 
abundance of vector population and vector competence for transmission of the disease needs to 
be studied. A total of 128 cases and 5 deaths were reported in 1998 which increased to 1600 
cases and 12 deaths in 2003 and 1150 cases and 8 deaths in 2005. 
 Recently, between October 2001 and January 2002, an epidemic of dengue emerged in 
Chennai, affecting adults and children; majority affected were children less than 15 yrs of age. 
DENGUE FEVER IN ADULTS 
Children were predominantly affected, but in recent years clinicians have seen increasing 
numbers of adult dengue patients17, with both significant morbidity and mortality. This rise in 
incidence among adults adversely affects developing countries economy. It also affects health 
planning, and is further compounded by the general lack of systematically collected information 
on the natural history of dengue in such patients. This often leads health planners and clinicians 
to base their decisions regarding resource allocation and clinical management on personal 
experiences8, rather than on tangible evidence. 
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Trends of increasing numbers of adult dengue patients can also be seen in other South 
Asian, South-East Asian and Latin American countries. If we are to take effective steps to reduce 
this trend and treat this group optimally, pooling information from different countries is 
important. At present, information on adult dengue infections in South Asia is quite limited. 
Adults9 differed in the clinical manifestations of dengue infection from children. It is 
necessary for health personnel to take these differences into consideration when identifying 
probable cases of dengue infection. Such data should be put to use in the recognition and 
management of cases. DHF, DSS and deaths has been reported among adults in various studies 
done in SEA region. 
G.N. Malavige et al8 has done one study in adult patients with confirmed dengue 
infections (n=108) treated in a general medical ward in Sri Lanka from 24 April to 31 July 2004. 
In this study, there were 68 male and 40 female patients, mean age was 26.6 years. Dengue fever 
(DF) was seen in 33 (30.6%) and dengue haemorrhagic fever (DHF) in 75 (69.4%). Of the 37 
(34.3%) with primary dengue infections, 19 (51.4%) developed DF and 18 (48.6%) developed 
DHF. Overall, 42 patients (38.9%) had bleeding manifestations. These adults showed differences 
in clinical and laboratory findings, disease severity and mortality, compared to children seen 
during the same epidemic. Secondary dengue infections were significantly associated with 
development of severe disease (OR 5.0, 95%CI 1.9–13.5, p < 0.001) Mortality was 3.7%. This 
study clearly demonstrates the Dengue infection pattern and complications among adults. 
Dengue studies were also done by Adriana O et al, NP Singh et al and Janak Kishore et 
al. Tthese studies gives the clinical and epidemiological pattern of Dengue infection among 
adults. 
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DENGUE VIRUS3 
 The dengue virus12 is a single stranded RNA virus belonging to the flaviviridae family. 
There are four serotypes (DEN 1–4), classified according to biological and immunological 
criteria. The viral genome is approximately 11 kb in length. The mature virion consists of three 
structural (core, membrane associated, and envelope) and seven non-structural (NS1, NS2a, 
NS2b, NS3, NS4a, NS4b, and NS5) proteins. The envelope protein is involved in the main 
biological functions of the virus. It binds to receptors on host cells, allowing the virus to be 
transported through it. In addition, the envelope protein is associated with haemagglutination of 
erythrocytes, induction of neutralising antibodies and protective immune responses. 
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Non-structural proteins (NS1–NS5) expressed as both membrane associated and 
secretory forms have also been implicated in the pathogenesis of severe disease.NS1 gets 
expressed on the surface of infected cells. Preliminary evidence suggests its involvement in viral 
RNA replication. Plasma levels of secreted NS1 (sNS1) correlate with viral titres, being higher in 
patients with DHF compared with dengue fever. Moreover, elevated free sNS1 levels within 72 
hours of onset of illness identify patients at risk of developing DHF. Very high levels of NS1 
protein are detected in acute phase samples from patients with secondary dengue infections but 
not primary infections. This suggests that NS1 may contribute to formation of circulating 
immune complexes, which are thought to have an important role in the pathogenesis of severe 
dengue infections. 
The dengue virus shares antigenic epitopes with other flaviviruses such as Japanese 
encephalitis virus. These shared epitopes may lead to production of cross reactive antibodies and 
hence interfere with serological diagnosis. However, antibodies directed to the prM protein of 
dengue viruses are species specific (not cross reactive with those of other flaviviruses) and may 
be useful for seroepidemiological36 studies in dengue (especially in countries where other 
flaviviruses are endemic). 
MOSQUITO VECTOR 
 Aedes14 is the vector for Dengue transmission. The genus includes Aedes aegypti, Aedes 
albopictus, and Aedes polynesiensis.The primary and most important vector is A aegypti, but A 
albopictus and A polynesiensis may also be involved. Aedes aegypti, a container breeding, day 
biting mosquito is found in tropical and subtropical areas.They rest indoors, mainly in living 
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rooms and bedrooms. This maximises man vector contact and minimises contact with 
insecticides sprayed outdoors, hence contributing to difficulty in controlling this vector. 
 Aedes aegypti can breed in polluted water or small collections water such as flower vases 
or coconut shells.Eggs can survive for long periods, as they are capable of withstanding 
desiccation. Improper disposal of garbage or inadequate wastewater drainage facilitates, both 
consequences of unplanned urbanisation, may be responsible for high mosquito densities in 
endemic areas. 
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Significant increases in the mosquito larval populations are seen during the rainy season. 
This may be a reason why epidemics of dengue tend to coincide with the rainy season. 
Furthermore, ambient temperature and relative humidity affect viral propagation in mosquitoes; 
rates being highest in climates resembling the rainy season. Environmental temperatures also 
affect the time for acute viraemia in female mosquitoes, being shorter with rises in temperature. 
 After biting an infected human, dengue viruses enter an adult female mosquito. The virus 
first replicates in the midgut, reaches the haemocoel and haemolymph, and then gains access to 
different tissues of the insect. After viral replication in the salivary glands, the infected mosquito 
can transmit the virus to another human. Ultrastructural studies show viral particles within the 
nervous system, salivary glands, foregut, midgut, fat body, epidermal cells, ovary and internal 
body wall lining cells of the mosquito. In contrast, they are absent from muscle, the hindgut, and 
malphigian tubules. Compared with uninfected mosquitoes, infected ones take longer to 
complete a blood meal. This may contribute to the efficiency of A aegypti as a dengue viral 
vector.  
 The existence of transovarial dengue virus transmission in aedes infected female mosqui- 
toes, allows propagation of virus to their progeny. Such a process would allow it to act as a 
reservoir for virus maintenance during interepidemic periods (without human or other vertebral 
host participation). Reports also suggest that dengue viruses may be transmitted sexually from 
the male to female mosquitoes, but not vice versa. 
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CLINICAL MANIFESTATIONS1 
 Dengue infection is a spectrum of disease ranging from asymptomatic to DSS. 
 
UNDIFFERENTIATED FEVER 
This usually follows a primary infection but may also occur during a secondary infection. 
Clinically it is indistinguishable from other viral infections. 
DENGUE FEVER 
Dengue fever may occur either as primary or secondary infection. The onset is sudden 
with high fever, severe headache (especially in the retro-orbital area), arthralgia, myalgia, 
anorexia, abdominal discomfort, and sometimes a macula-papular rash. The fever may be 
biphasic and tends to last for 2–7 days. Flushing, a characteristic feature is commonly observed 
on the face, neck, and chest. Coryza may also be a prominent symptom especially in infants. 
Younger children tend to present with coryza, diarrhoea, rash and seizure, and less commonly 
16 
 
with vomiting, headache, and abdominal pain. Although, haemorrhagic manifestations are 
uncommon in dengue fever, petechiae/pupura, gastrointestinal bleeding, epistaxis, and gingival 
bleeding have been observed in some individuals. A positive tourniquet test has been reported in 
many individuals with dengue fever possibly due to reduced capillary fragility. Recovery from 
dengue fever is usually uneventful, but may be prolonged especially in adults. 
DENGUE HAEMORRHAGIC FEVER 
DHF usually follows secondary dengue infections, but may sometimes follow primary 
infections, especially in infants. In such infants, maternally acquired dengue antibodies are 
presumed to enhance primary infections. Such a phenomenon has not been described in human 
infections other than dengue. DHF11 is characterised by high fever, thrombocytopenia, 
haemorrhagic phenomena, and features of circulatory failure. For purposes of description DHF is 
divided into three phases—namely: febrile, leakage, and convalescent phases. Furthermore, 
according to severity DHF is divided into four grades. 
 The febrile phase begins with sudden onset fever accompanied by generalized 
constitutional symptoms and facial flush.The fever is high grade, intermittent, and associated 
with rigors. Epigastric discomfort, myalgia, vomiting, and abdominal pain are common and 
patients are usually quite miserable. Sore throats and febrile convulsions may be seen, especially 
among young children. Tender hepatomegaly is observed in almost all patients and 
splenomegaly may be seen in some. A macular papular rash similar to that seen in dengue fever 
is also seen in many patients. The fever lasts for 2–7 days and is followed by a fall in 
temperature to normal or subnormal levels. At this point, the patient may recover or progress to 
the phase of plasma leakage. Those who remain ill despite their temperature subsiding are more 
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likely to progress to DHF. Clinical deterioration usually occurs during defervescence (often 
between days 3 and 4) 
PLASMA LEAKAGE MANIFESTATIONS3 
 Tachycardia and hypotension characterise the onset of plasma leakage. When plasma 
leakage is severe, patients may develop other signs of circulatory disturbance such as prolonged 
capillary refill time, narrow pulse pressures, and shock. Inadequate treatment of such patients 
often leads to profound shock. During the phase of plasma leakage (first 24–48 hours after onset 
of DHF), pleural effusions and ascites are common. Pleural effusion is usually seen on the right 
side; a right decubitus chest radiograph or ultrasound chest is best for detecting small effusions. 
Abdominal ultrasound scans may demonstrate ascites or a oedematous gall bladder wall. 
Pericardial effusions may also occur. This latter complication is uncommon, but is associated 
with high morbidity and mortality. 
 In DHF, bleeding may occur from any site and does not correlate with the platelet counts. 
Haemorrhagic manifestations usually occur once the fever has settled. Minor degrees of bleeding 
may manifest as gum bleeding and petechiae. The commonest site of haemorrhage is the 
gastrointestinal tract, which manifests as haematemesis or melaena, followed by epistaxis. 
Vaginal bleeding is commonly reported in females. 
 Convalescence in DHF is usually short and uneventful. The return of appetite is a good 
indicator of recovery from shock. Bradycardia is also seen in this period. If present, a confluent 
petechial rash with erythema and islands of pallor (usually known as a recovery rash) is 
18 
 
characteristic of dengue infections. During the convalescent stage, many patients also complain 
of severe itching especially on the palms and soles. 
DENGUE SHOCK SYNDROME3 
 Severe plasma leakage leads to decreased intravascular volume followed by hypotension 
& shock. Usually occurs 3-7 days after the onset of fever. DSS manifests as cold clammy 
skin,circumoral cyanosis, severe abdominal pain, tachycardia, hypotension & shock. Prolonged 
shock may leads to metabolic acidosis which aggravates coagulopathy, leads to DIC and massive 
haemorrhage. Sometimes may be associated with encephalopathy. If shock is not corrected 
patient may die within 12-24hrs.patients may recover from shock in 2-3days with effective 
supportive management. 
DIFFERENTIAL DIAGNOSIS OF DENGUE FEVER AND DHF1 
 DENGUE FEVER 
Infectious mononucleosis, Chickengunya viral infections, Coxsackie and other 
enteroviral infections, Rickettsial infections, Leptospirosis and Influenza 
DHF 
Leptospirosis, Chikengunya viral infections, Kawasaki disease, Yellow fever, 
Hanta viral infections, Other viral haemorrhagic fevers and Meningococcal septicemia. 
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LABORATORY FINDINGS 
 In most cases of dengue fever, platelet counts and serum biochemistry are normal. 
However, leucopenia, thrombocytopenia, and raised liver enzymes may be seen. In contrast, 
DHF is always accompanied by a platelet count ,<100x109/l, haemoconcentration (a rise in the 
packed cell volume .20% of basal levels), leucopenia, and raised liver enzymes  Elevation of 
both alanine and aspartate aminotransferase levels occur with plasma aspartate aminotransferase 
levels being higher in children who develop DHF than in those with dengue fever. 
 A leucopenia of 5x109/l has been suggested to predict the onset of DHF. Initial 
leucopenia is followed by a relative lymphocytosis (with more than 15% atypical lymphocytes) 
towards the end of the febrile phase. Abnormal coagulation profiles (prolonged partial 
thromboplastin time and prothrombin time, raised fibrinogen degradation products), 
hypoalbuminaemia, and reduced serum complement levels are also seen. These coagulation 
abnormalities suggest that there is activation of both coagulation and fibrinolysis during acute 
infection and the degree of activation being greater in severe DHF and dengue shock syndrome. 
COMPLICATIONS3 
 Severe dengue infections may give rise to many complications such as liver failure, 
disseminated intravascular coagulation, encephalopathy, myocarditis, acute renal failure, and 
haemolytic uraemic syndrome. 
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LIVER FAILURE 
Since hepatocytes and Kupffer cells support viral replication, liver involvement is 
common in all forms of dengue infection. Levels of aspartate transaminase and alanine 
transaminase are significantly higher, and globulins significantly lower among patients with the 
more severe grades of DHF. Fulminant liver failure can occur due to hepatitis or focal necrosis 
of the liver causing hepatic encephalopathy and even death. Jaundice may be present. 
Neurological examination may show hyper-reflexia or an extensor plantar response. Electrolyte 
abnormalities and hypoglycaemia may accompany liver enzyme abnormalities. 
ENCEPHALOPATHY18 
 Encephalopathy has been reported in 0.5% of patients with DHF, and has a mortality rate 
of 22%.  Many factors contribute towards development of encephalopathy including: hepatic 
dysfunction, electrolyte imbalances, cerebral oedema (caused by vascular changes leading to 
fluid extravasation), hypoperfusion (due to circulatory disturbances), and dengue encephalitis. 
The dengue virus has been isolated from the cerebrospinal fluid of some patients having features 
of encephalitis. Other neurological manifestations such as altered consciousness, seizures, 
spasticity of limbs, hemiplegia, and a positive Kernig’s sign have also been reported in 5.4% of 
patients with dengue. 
MYOCARDITIS 
Acute reversible myocarditis19 has been reported in patients with dengue infections. ST 
segment and T wave changes in the electrocardiogram together with low ejection fractions and 
global hypokinesia on radionuclide ventriculography have been found. No myocardial necrosis 
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was detected in any of the patients. In another study, 16.7% of children had left ventricular 
dysfunction when assessed by two dimensional and colour Doppler echocardiography. The left 
ventricular failure may contribute to hypotension seen in DHF/dengue shock syndrome and may 
have implications in fluid management as fluid overload may worsen the condition. 
DIAGNOSIS 
CLINICAL DIAGNOSIS 
WHO CASE DEFINITIONS FOR DENGUE INFECTION1 
CASE DEFINITION FOR DENGUE FEVER 
 The following classifications are proposed: 
 Probable: an acute febrile illness with two or more of the following manifestations: 
 Headache 
 Retro-orbital pain   
 Myalgia 
 Arthralgia 
 Rash 
 Haemorrhagic manifestations 
 Leukopenia 
And  
 Supportive serology (a reciprocal haemagglutination-inhibition antibody titre 
≥ 1280, a comparable IgG enzyme-linked immunosorbent assay  titre or a 
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positive IgM antibody test on a late acute or convalescent-phase serum 
specimen) 
Or  
 Occurrence at the same location and time as other confirmed cases of dengue 
fever. 
Confirmed: case confirrmed by laboratory criteria  
Reportable: any probable or confirrmed case should be reported. 
LABORATORY CRITERIA  
 Isolation of the dengue virus from serum or autopsy samples; or 
 Demonstration of a fourfold or greater change in reciprocal IgG or IgM 
 Antibody titres to one or more dengue virus antigens in paired serum samples; 
or 
 Demonstration of dengue virus antigen in autopsy tissue, serum or cerebro 
spinal fluid samples by immunohistochemistry, immunoflouorescence or 
ELISA; or 
 Detection of dengue virus genomic sequences in autopsy tissue serum or 
cerebrospinal fluid samples by polymerase chain reaction (PCR). 
CASE DEFINITION FOR DENGUE HAEMORRHAGIC FEVER 
The following must all be present: 
 Fever 
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 Haemorrhagic tendencies, evidenced by at least one of the following: 
- a positive tourniquet test 
- petechiae, ecchymoses or purpura 
- bleeding from the mucosa, gastrointestinal tract, injection sites or other 
locations. 
- haematemesis or melaena. 
 Thrombocytopenia (≤ 100000 cells per mm3) 
 Evidence of plasma leakage due to increased vascular permeability, 
manifested by at least one of the following: 
- rise in the haematocrit equal to or greater than 20% above average for 
age, sex and population; 
- drop in the haematocrit following volume-replacement treatment equal 
to or greater than 20% of baseline; 
- signs of plasma leakage such as pleural effusion, ascites and 
hypoproteinaemia. 
CASE DEFINITION FOR DENGUE SHOCK SYNDROME 
 All of the above four criteria for DHF must be present, plus evidence of circulatory 
failure manifested by: 
 Rapid and weak pulse. 
 Narrow pulse pressure (≤20mmHg). 
 Hypotension for age and cold clammy skin and restlessness . 
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GRADING SEVERITY OF DENGUE HAEMORRHAGIC FEVER 
 Grade-I   :  Fever + Thrombocytopenia +Plasma leak + Tourniquet Test positive  
 Grade -II: Grade I + Spontaneous Bleeding 
 Grade III:  Grade II + narrow pulse Pressure or hypotension 
            Grade IV: Grade II + Profound Shock 
Grade III and IV are considered as Dengue Shock Syndrome (DSS) 
TOURNIQUET TEST (HESS TEST)1 
 By inflating a blood pressure cuff on the upper arm to a point midway between the 
systolic and diastolic pressures for 5 minutes. A test is considered positive when 20 or more 
petechiae per 2.5cm (1 inch) square are observed. The test may be negative or mildly positive 
during the phase of profound shock. It usually becomes positive, sometimes strongly positive, if 
the test is conducted after recovery from 
shock. 
 
 
Tourniquet test positive 
 
 Overall, a positive standard tourniquet test is reasonably specific for dengue infection, if 
performed on children suspected to have dengue in an endemic area where the probability of 
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dengue is high. It should be remembered that a negative test does not exclude dengue infection. 
A careful inspection of the skin for petechiae or other bleeding can contribute importantly to the 
correct diagnosis. 
 The tourniquet test should be regarded as suggestive of dengue infection but not used as 
an absolute criterion for making the diagnosis. Nor is the test helpful in defining the severity of 
illness. It can be difficult to interpret in dark-skinned individuals. The fact that petechiae may be 
difficult to observe on dark skin may contribute to the differences seen in the results of the 
tourniquet test in different populations. The time taken to perform a tourniquet test may be better 
applied to an overall assessment of the patient with suspected dengue infection1. 
 
 
26 
 
PATHOGENESIS OF DENGUE FEVER/DHF 
 Dengue may be caused by any of the dengue viral serotypes.Generally, infection with one 
serotype confers future protective immunity against that particular serotype but not against other 
serotypes. Furthermore, when infected for a second time with a different serotype, a more severe 
infection may occur. This is due to a phenomenon referred to as antibody dependent 
enhancement, where antibodies against the first serotype enhance infection with the second 
serotype. However, as only 2%–4% of individuals with a secondary dengue infection develop 
severe disease, antibody dependent enhancement alone cannot wholly explain this process. At 
present, reasons as to why only some individuals develop symptomatic infection are not known, 
but active research is being pursued by several groups to clarify such mechanisms. 
After the bite of an infected mosquito, the dengue virus enters the body and replicates 
within cells of the mononuclear phagocyte lineage (macrophages, monocytes, and Bcells). 
Additionally, infection of mast cells, dendritic cells, and endothelial cells are known to occur. 
The incubation period of dengue infections is 7–10 days. A viraemic phase follows where the 
patient becomes febrile and infective. Thereafter, the patient may either recover or progress to 
the leakage phase, leading to DHF and/or dengue shock syndrome. Peak plasma viraemia 
correlates with the severity of dengue infections. Differences in antibody, cytokine, and T-cell 
responses are seen among patients with uncomplicated dengue fever or DHF/dengue shock 
syndrome.  
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1. ANTIBODY RESPONSES TO THE DENGUE VIRUS 3,20.22 
 
Antibody dependent enhancement is thought to play a key part in the pathogenesis of 
severe dengue infections. During secondary dengue infections, antibodies already present in the 
patient form complexes with the dengue virus. The Fc portion of these antibodies can then bind 
to FccRI and FccRII bearing cells and result in an increased number of cells being infected by 
the dengue virus. Antibody dependent enhancement is found to occur only in the presence of 
subneutralising concentrations of dengue antibodies. 
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2. CYTOKINE RESPONSES IN DENGUE INFECTIONS3,21,23 
TNF-α, IL-2, IL-6 and IFN-γ increased in initial 3 days.IL-13 and IL-18 is very high in 
severe infection. IL-2 and IFN-γ are Th1 type, IL-5 and IL-4 Th2 type cytokines. Thus, it has 
been suggested that Th1 responses are seen during the first 3 days and Th2 responses occur later. 
Increased levels of IL-13 and IL-18 have also been reported during severe dengue infections, 
with highest levels seen in patients with grade IV DHF. Serum IL-12 levels are highest in 
patients with dengue fever, but undetectable in patients with grade III and IV DHF. 
DHF patients have higher levels of TNF-α, IL-6, IL-13, IL-18, and cytotoxic factor 
compared with DF patients. These cytokines have been implicated in causing increased vascular 
permeability and shock during dengue infections24.  
Increased levels of TNF-α and IL-10 correlate with haemorrhagic manifestations and 
platelet decay respectively. IL-10 may also down-regulate platelet function and thus contribute t 
platelet defects associated with dengue infections. 
 
3. CELLULAR IMMUNE RESPONSES IN DENGUE INFECTIONS3,20 
Suppression of T-cell responses25 can occur in dengue fever and DHF. This could persist 
for at least two weeks after the onset of fever. In one study, respiratory tract infections or 
diarrhoea were seen in 6% of patients after dengue infections. This suppression has been 
suggested to be due to a primary defect within antigen presenting cells. IL-10, whose levels are 
increased in DHF, is known to down-regulate antigen presenting cell responses and induce 
unresponsiveness in T-cells. 
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Primary infection  
Activation of CD4 & CD8  
Memory cells of both  
Secondary infection  
Activation memory CD4 cell  
Release of IFN-γ, TNF-α & TNF-β  
Augments dengue virus uptake by engulfing  
Up regulation of Fc receptor  
Dengue virus multiplication  
CD4:CD825  reversal  
CD 8 releases multiple cytokines  
DHF  
SPECIAL ISSUES  
THROMBOCYTOPENIA24 
 Early bone marrow suppression, prolonged megakaryocyte arrest 
 Increased peripheral destruction – immune mediated, spleen mediated 
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Platelet dysfunction also occurs. Impairment of ADP releasing ability of platelets, 
thereby causing  impairment of platelet aggregation. 
COAGULOPATHY24,41  
 Coagulopathy is most important complication in dengue viral infection 
Factors causing coagulopathy37 are; 
 Thrombocytopenia 
 PT,aPTT prolongation; decreased fibrinogen level. 
 Decreased II,V,VII,VIII,IX & X factors 
 Mechanisms causes spontaneous activation of fibrinolysis. 
GI bleeding is most common bleeding manifestation followed by epistaxis.Due to plasma 
leakage the drop in hematocrit is not evident due to hemcoancentration38. In later stage thee will 
be a vicious cycle of unresponsiveness shock, massive fluid replacement, fluid overload, 
worsening of metabolic state and further worsens bleeding. So recognization of hypotension & 
shock and treatment of   them is essential. 
PLASMA LEAKAGE41 
 There is increase in microvascular permeability that leads to plasma leakage followed by 
hypotension & shock. The exact mechanism remains unknown. Vascular permeability present in 
all type of Dengue illness. 
 There will be sudden & marked increase in microvascular permeability which allows 
plasma water to flood out of the intravascular compartment and leads to sudden hypovolemic 
shock, as the compensatory mechanisms ( increased lymphatic drainage, reabsorption capacity) 
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fail to cope. Capillary permeability of growing children is twice that of healthy adults. This 
higher microvascular permeability in childhood result from the greater density and surface area 
of microvessels in children than in adults, and explains why children are more prone to develop 
Dengue shock syndrome than adults. 
 
 
 
 Alterations occur in endothelial glycocalyx layer in vessel wall, which is act as a 
electrostatic barrier in vascular wall and repelling negatively charged plasma proteins from 
endovascular surface. Dengue NS protein or immune response directly damages glycocalyx and 
alters fiber matrix of the layer. The fast recovery from endothelial permeability evidences the 
possibilities of reversible factors disturbances rather than structural damage to vascular wall. 
Cytokines also play role in causing increased vascular permeability ( IL-1,IL-2,IL-6,TNF-α,IFN-
γ, VEGF)  
HOST GENETIC FACTORS 
 Severe dengue infections are seen in only a minority (2%–4%) of patients with secondary 
dengue infections. A few studies have looked at the effect of polymorphisms at the major 
histocompatibility complex locus on susceptibility to DHF. Loke et al carried out molecular 
HLA typing of patients with DHF in Vietnam. They found that polymorphism at the HLA class I 
loci was significantly associated with DHF disease susceptibility, but polymorphism in the HLA-
DRB1 or TNF genes were not. Furthermore, this association was confined to the HLA-A region 
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and not the HLA-B gene. Children with HLA-A*33 were less likely and those with HLA-A*24 
more likely to develop DHF. 
LABORATORY DIAGNOSIS 
Methods used for diagnosis of dengue infections are: 
 1. Virus isolation, 
2. Serology 
3. Molecular techniques 
1. VIRUS ISOLATION: 
 Detection of dengue virus by culture is the defininitive diagnostic test, but practical 
considerations limit its use. During the febrile phase, dengue viruses can be isolated from serum, 
plasma, or leucocytes. It can also be isolated from postmortem specimens such as liver, lung,\ 
spleen, lymph nodes, thymus, cerebrospinal fluid, or pleural/ascitic fluid. Ideally, blood should 
be collected during the febrile period, preferably before the fifth day of illness (that is, before 
formation of neutralising antibodies). Formation of immune complexes due to the presence of 
large quantities of neutralising antibodies in secondary dengue patients may interfere with virus 
isolation. For short periods of time (less than 24 hours) serum can be kept at 4–8˚ C, but for 
longer periods should be stored at 270˚ C.  
Virus isolation done by 
  Mosquito cell lines. 
 Mosquito inoculation technique. 
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 Vertebral cell culture. 
Currently, inoculation of C636 mosquito cell lines (obtained from A albopictus) is the 
method of choice. Virus isolation is done for research purposes only as it needs expertise, takes 
two weeks to read the results, and is expensive. 
SEROLOGICAL DIAGNOSIS 
Methods are: 
 Haemagglutination inhibition tests 
 Enzyme linked immunosorbent assay (ELISA) 
 Complement fixation test 
 Neutralisation tests 
2. HAEMAGGLUTINATION INHIBITION TESTS 
 The HI test is simple, sensitive and reproducible and has the advantage of using reagents 
that may be prepared locally. HI test26 requires paired sera. Paired sera are most easily obtained 
upon hospital admission (acute) and discharge (convalescent). The HI test is based on the ability 
of dengue virus antibodies27 to inhibit this agglutination. A fourfold or greater rise in antibody 
titres is suggestive of a flavivirus infection (and not diagnostic of dengue infections). However, a 
single antibody titre >1/2560 is accepted as indicating secondary dengue infection if supported 
by a clinical history suggestive of dengue.Based on this principal Dengue Card Test (Panbio 
duocasste) formed. 
 
 
34 
 
DENGUE CARD TEST40 
 
   
 
 
 
MAC-ELISA  
In primary or secondary dengue infections, MAC-ELISA28 can measure a rise in dengue 
specific IgM, even in sera samples collected at 1-day to 2-day intervals in the acute phase. 
Specimens collected over an interval of 2–3 days spanning the day of defervescence are also 
usually diagnostic in MAC-ELISA. In cases where only a single specimen is available, detection 
of anti-dengue IgM permits the diagnosis of recent dengue infection. 
Invalid test 
Primary  Dengue Infection 
Secondary Dengue Infection 
Sample addition & Running buffer addition 
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 Detection of IgM in cerebrospinal fluid is a significant diagnostic finding, implying 
flavivirus replication within the CNS. 
3. MOLECULAR DETECTION 
RT-PCR is useful for the detection of dengue infection early in the disease when 
antibodies are not detected. RT-PCR is more sensitive than virus isolation, allows for rapid 
detection of dengue infections (results are usually available in 24 hours) and easier identification 
of the circulating serotype. It is useful for epidemiological studies as dengue serotypes could be 
identified without cross reactivity with other flaviviruses. The downside of molecular techniques 
is its relatively high cost and the expertise needed. 
MANAGEMENT1,4 
Febrile Phase: 
In the initial phase the treatment of DF & DHF is the same and is as that of any other viral fever, 
i.e. symptomatic and supportive. 
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 Rest. 
 Paracetamol  
 Do not give Aspirin or Brufen. Aspirin can cause gastritis and/or bleeding. In children, 
Reye’s syndrome (Encephalopathy) may be a serious complication. 
 Do not give antibiotics as these do not help. 
 Oral Rehydration Therapy is recommended as there may be mild to moderate 
Dehydration due to vomiting & high temperature.. 
DENGUE HEMORRHAGIC FEVER 
Patients with known or suspected DF30 should have their platelet count and Hematocrit 
measured daily from the third day of illness until 1-2 days after defervescence. Those patients 
with a rising Hematocrit or falling platelet count should have intravascular volume deficits 
replaced. Those patients who improve can continue to be monitored in an outpatient setting. 
Those patients who do not improve should be admitted to the hospital for continued hydration. 
INDICATIONS OF HOSPITALIZATION  
 Patients who develop signs of Tachycardia 
 ↑ Capillary Refilling Time ( > 2 sec) 
 Cool and clammy extremities 
 Diminished peripheral pulses 
 Changes in Mental status 
 Oliguria  
 Sudden rise in Hematocrit 
 Narrowing of pulse pressure ( < 20 mm Hg ) 
 Hypotension ( Late finding-Uncorrected shock ) 
The fluid used to correct dehydration is chosen according to the nature of the fluid loss. 
In cases of isotonic dehydration, 5% glucose (50g/l) diluted 1:2 or 1:1 in physiological (normal) 
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saline should be used. Bicarbonate-containing solutions should not be used for the initial 
intravenous management of dehydration in DHF, and should be reserved for cases where there 
are persistent fluid losses from diarrhoea. 
The necessary volume of replacement fluid is equivalent to the amount of fluid and 
electrolyte lost: thus, 10ml/kg should be administered for each 1% of normal body weight lost. 
Maintenance fluid requirements, calculated according to the Halliday & Segar formula, should 
be added to the replacement fluid volume. Since the rate of plasma leakage is not constant (it is 
more rapid when body temperature drops) the volume and rate of intravenous fluid therapy 
should be adjusted according to the volume and rate of plasma loss. Plasma loss can be 
monitored by changes in the haematocrit, vital signs or volume of urine output. 
HALLIDAY & SEGAR FORMULA   
 
Body weight (kg) 
Maintenance volume (ml) administered 
over 24 hours 
10 
10-20 
>20 
100/kg 
1000 + 50 per each kg in excess of 10 
1500 + 20 per each kg in excess of 20 
 
BLOOD TRANSFUSION 
 Blood transfusion is only indicated in cases with significant clinical bleeding. Internal 
bleeding may be difficult to recognize in the presence of haemoconcentration. A drop in 
haematocrit, e.g. from 50% to 40%, with no clinical improvement despite adequate fluid 
administration, indicates a significant internal haemorrhage. Transfusion with fresh whole blood 
is preferable. Fresh frozen plasma or concentrated platelets (if <20,000 or <50,000 with 
bleeding) may be indicated in cases where coagulopathy causes massive bleeding. 
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VOLUME REPLACEMENT FLOW CHART FOR DHF32  
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VOLUME REPLACEMENT FLOW CHART FOR DS31,32 
 
 
FLUIDS RECOMMENDED: 
Crystalloids33 : 
  5% Dextrose in Isotonic NS 
  5% Dextrose in ½ NS 
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  5% Dextrose in RL 
  Shock Correction NS or RL  
Colloids : 
  Dextran 40 
  Hemaccel  
 Plasma  
Monitoring of patients in DSS 
 Check vitals every 15-30 minutes until shock is overcome. 
 Check HCT / Platelets for every 2 hours for the first 6 hours and every 4 hours 
until stable. 
 Fluid balance sheet to be maintained. Frequency & volume of urine output to be 
recorded. In refractory shock catheter may be needed. 
CRITERIA FOR DISCHARGE 
Patients who are resuscitated from shock recover rapidly. Patients with DHF or dengue shock 
syndrome (DSS) may be discharged from the hospital when they meet the following criteria: 
 Afebrile for 24 hours without antipyretics  
 Good appetite, clinically improved condition  
 Adequate urine output  
 Stable Hematocrit  
 At least 48 hours have passed since recovery from shock  
 Absence of respiratory distress  
 Platelet count greater than 50,000. 
PREVENTION AND CONTROL OF DHF 
                    Since there is no effective vaccine against dengue, the prevention and control of 
dengue infections depends largely on preventing man-vector contact. Numerous strategies have 
been adopted and include: environmental control, biological control, chemical control, and active 
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case surveillance. While each of these methods have some effect, successful control programmes 
should incorporate all appropriate methods and also foster a strong partnership between the 
different dengue control agencies and the community. The dengue control programmes in the 
South East Asian and South Asian regions have been generally unsuccessful, largely because 
they have relied solely on insecticide spraying. 
ENVIRONMENTAL CONTROL METHODS 
            These include: reducing vector breeding sites, solid waste management, modification of 
manmade breeding sites, and improvements in house design. Public education programmes play 
a vital part if they are to be effective. Personal protection is important in preventing man-vector 
contact. Sufficiently thick and loose fitting clothes reduce contact with the mosquitoes, but may 
not be the most practical clothes to wear in hot tropical climates. Other measures such as using 
household insecticidal products (mosquito mats and liquid vaporisers) or mosquito repellents 
may also be effective. Naturally occurring repellents (citronella oil, lemon grass) or chemical 
repellents (DEET) are available. However, unlike in the control of malaria,insecticide treated 
mosquito nets have limited utility in dengue as the vector is chiefly a day biting mosquito. 
 
BIOLOGICAL CONTROL OF VECTOR: 
             Biological control methods are targeted against the larval stages of the dengue vector. 
They include the use of larvivorous fish such as Gambusia affinis and Poecilia reticulate, 
endotoxin producing bacteria (Bacillus thuringiensis serotype H-14 and Bacillus sphaericus are 
currently used), and copepod crustaceans. Bacillus thuringiensis serotype H-14 is more effective 
against A aegypti with very low levels of mammalian toxicity, and has therefore been accepted 
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for use in household containers storing water.2 The use of mesocyclops (a copepod crustacean) 
in the Northern Province of Vietnam led to the eradication of the vector in a many areas. 
CHEMICAL CONTROL 
              This includes the application of larvicidal insecticides or space spraying. Space spraying 
is more widely used as larvicidal insecticides cost more. Insecticides used for treating containers 
that hold water includes Temephos 1% sand granules andinsect growth regulators. Regular 
monitoring of resistance patterns is essential as resistance to Temephos has been reported among 
some aedes mosquito species in the South East Asian Region. Insect growth regulators interfere 
with the development of the immature forms of the mosquito and have extremely low 
mammalian toxicity. Space spraying may be applied as thermal fogs or as ultralow volume 
sprays. Although both methods are equally effective in killing adult mosquitoes, thermal fogging 
tends tobe used more widely. 
CURRENT STATUS OF THE DENGUE VACCINE34 
Much research has been carried out to develop a dengue vaccine that is safe and 
immunogenic against all four serotypes. Although many of the vaccines developed so far(live 
attenuated, chimeric, DNA, and subunit vaccines) show promising results, none are sufficiently 
immunogenic for routine use. 
 
 
 
 
 
  
 
MATERIALS AND 
METHODS   
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MATERIALS AND METHODS 
 
 This study was done in >13yrs patients admitted to adult General Medical ward of 
Stanley Medical College Hospital, Chennai from August 2007 – January 2009.  
 All patients with clinical features of Dengue infection and positive for Dengue Card Test 
(PANBIO card Test) were taken up for the study. Their Clinical profile, Laboratory data and 
Outcome were recorded. 
1. All the patients were evaluated for  
 a). Clinical Features 
 Fever 
 Headache  
 Retro orbital pain (ROP) 
 Myalgia and Arthralgia 
 Abdominal pain 
 Nausea/ Vomiting 
 Diarrhea/ Constipation 
 Sleeplessness/ Lethargy 
 Facial flush 
 Conjunctival injection 
 Lymphadenopathy 
 Hepatospleenomegaly 
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 Bleeding manifestations 
 Plasma leakage manifestations 
b). Laboratory parameters 
 Haemogram – TC, DC, Platelets 
 Renal function – Urea, Creatinine 
 Blood sugar 
 Liver Function Test 
 Chest X-ray 
 Ultra-Sound Abdomen 
 Dengue Card Test 
2. Statistical Analysis 
 The relationship between the frequencies of clinical parameter of Dengue Fever (DF) and 
Dengue Haemorrhagic Fever (DHF)  were analyzed after construction of 2x2 table and applying 
the Statistical Test of significance Chi-Squared Test of significance or Fisher`s eχ2   test. 
3. Exclusion criteria  
 Patients with malaria, Enteric fever, Leptospirosis and Pneumonia were excluded by 
doing appropriate investigations. 
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4. Following WHO criteria were adopted to define DF/DHF/DSS 
 CASE DEFINITION FOR DENGUE FEVER 
 The following classifications are proposed: 
An acute febrile illness with two or more of the following manifestations: 
 Headache 
 Retro-orbital pain   
 Myalgia 
 Arthralgia 
 Rash 
 Haemorrhagic manifestations 
CASE DEFINITION FOR DENGUE HAEMORRHAGIC FEVER 
The following must all be present: 
 Fever 
 Haemorrhagic tendencies, evidenced by at least one of the following: 
- a positive tourniquet test 
- petechiae, ecchymoses or purpura 
- bleeding from the mucosa, gastrointestinal tract, injection sites or other 
locations. 
- haematemesis or melaena. 
 Thrombocytopenia (≤ 100000 cells per mm3) 
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 Evidence of plasma leakage due to increased vascular permeability, 
manifested by at least one of the following: 
- rise in the haematocrit equal to or greater than 20% above average for 
age, sex and population; 
- drop in the haematocrit following volume-replacement treatment equal 
to or greater than 20% of baseline; 
- signs of plasma leakage such as pleural effusion, ascites and 
hypoproteinaemia. 
CASE DEFINITION FOR DENGUE SHOCK SYNDROME 
 All of the above four criteria for DHF must be present, plus evidence of circulatory 
failure manifested by: 
 Rapid and weak pulse. 
 Narrow pulse pressure (≤20mmHg). 
 Hypotension for age and cold clammy skin and restlessness . 
GRADING SEVERITY OF DENGUE HAEMORRHAGIC FEVER 
 Grade-I   :  Fever + Thrombocytopenia +Plasma leak +  Tourniquet Test positive  
 Grade -II: Grade I + Spontaneous Bleeding 
 Grade III:  Grade II + narrow pulse Pressure or hypotension 
            Grade IV: Grade II + Profound Shock 
Grade III and IV are considered as Dengue Shock Syndrome (DSS) 
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5. Management 
All patients who suffered from fever were treated with paracetamol and bed rest. Those 
patients, who went for complications like DHF, were treated with WHO protocol. 5% DNS was 
used for all cases of Dengue Hemorrhagic Fever as IV fluid therapy. All DHF –II patients were 
started with IV crystalloids with rate of  6-7 ml/kg/hr and their improvement noted with 
Haematocrit value. If Patient deteriorated further aggressive management for Dengue Shock 
Syndrome was started with 10ml/kg/hr. If there is no improvement with this management, then 
15ml /kg/hr rate of IV crystalloid was given. If Patient developed intractable Shock, further 
management was based on Haematocrit value. If there is fall in Haematocrit, Blood transfusion 
was given. If Haematocrit showed a rise, IV colloid therapy was indicated. Platelet transfusion 
was done in patients with bleeding manifestations with platelet <50,000 or platelet count 
<20,000 even without Bleeding manifestation. 
 
 
 
 
 
 
 
 
  
 
RESULTS  
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RESULTS 
 
Total no of patients   : 122 
No of Dengue Fever (DF)  : 71 (58%) 
No of Dengue Haemorrhagic Fever : 51 (42%) 
 DHF – I   : 4 (3%) 
 DHF – II    : 35 (30%) 
 DHF – III    : 9 (7%) 
 DHF – IV    : 3 (2%) 
 
AGE – SEX DISTRIBUTION FOR DENGUE INFECTION 
 Mean Age  : 29 ± 13.5 yrs 
 About 65%  of patients were in the age group of 13 to 40 yrs. 
 66% were Male and 34% were Females 
 Sex ratio -   M:F = 1.9:1 
 
 
30%
7% 2%
42%
DHF
SPECTRUM  OF  DENGUE  INFECTION
58%
3%
Dengue Fever DHF-I DHF-II DHF-III DSS
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Table1. Age – Sex distribution for dengue infection 
AGE GROUP MALE FEMALE TOTAL 
13 – 20 yrs 32 12 44 
21 – 30 yrs 22 13 35 
31 – 40 yrs 16 7 23 
41 – 50 yrs 5 7 12 
51 – 60 yrs 3 0 3 
>60 yrs 2 3 5 
TOTAL 80 (66%) 42 (34%) 122 
 
AGE – SEX DISTRIBUTION FOR DHF 
Table 2. Age – Sex distribution for DHF 
n = 51 DHF 
n=51 
DHF – I 
n=4 
DHF – II 
n=35 
DHF – III 
n=9 
DHF – IV 
n=3 
MALE 32 (26%) 3 22 6 1 
FEMALE 19 (16%) 1 13 3 2 
13 – 30 yrs 32 3 19 8 2 
31 – 50 yrs 18 1 15 1 1 
51 – 65 yrs 1 0 1 0 0 
> 65 yrs 0 0 0 0 0 
 
50
60
70
80
90
100
110
120
N
o
 
o
f
 
C
a
s
e
s
AGE – SEX  DISTRIBUTION
0
10
20
30
40
Total yrs 13-20 21 -30 31 -40 41-50 51-60 >60 
Female 42 12 13 7 7 0 2
Male 80 32 22 16 5 3 2
N
o
 
o
f
 
C
a
s
e
s
50 
 
 Dengue Haemorrhagic Fever (DHF) commonly in the Age group of 13 – 40 yrs. Elderly 
patients were not affected with DHF. 
 Mean Age  : 29 ± 11 yrs 
 63% were males and 37% were females 
 Sex ratio -  : M:F = 1.7:1 
 
SEASONAL DISTRIBUTION  
 Most cases occurred in the month between September to January. Around 78 (64%) cases 
were reported in the year of 2007 and the number reduced to 44 (36%) in 2008. 
Table 3. Seasonal Case Incidence 
MONTH NO OF CASES (n=122) 
Aug – Sep 07 6 
Oct – Nov 07 39 
Dec 07 – Jan 08 38 
Feb – Mar 08 6 
Apr – May 08 0 
Jun – Jul 08 1 
Aug – Sep 08 10 
Oct – Nov 08 19 
Dec 08 – Jan 09 3 
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Primary Infection   : 29 (24%) 
Secondary Infection  : 93 (76%) 
Secondary infection causes DHF in 48 cases; only 3 cases were primary infection. 
 
CLINICAL FEATURES 
FEVER 
 Fever occurs in all (100%) patients. 
 Mean duration of fever     : 4.9 ± 1 days 
 Mean duration of fever before admission  : 2.5 days 
 High grade fever     : 69% patients 
 Continuous type of fever    : 41% patients 
OTHER CLINICAL SYMPTOMS 
 Myalgia ( 82%), Arthralgia (65%) and Headache (77%) were common symptoms after 
fever. 
 Arthralgia, Abdominal pain, Nausea/Vomiting, altered bowel movements, Sleeplessness 
and lethargy were statistically significant symptoms that occurred in DHF as compared to 
Dengue fever. 
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Table 4. Clinical Symptoms 
SYMPTOMS Total 
n=122 
DF 
n=71 
DHF 
n=51 P value 
HEADACHE 77%(94) 73%(52) 82%(42) 0.2797 
RETRO ORBITAL 
PAIN 12%(15) 13%(9) 12%(6) 1 
MYALGIA 82%(100) 86%(61) 76%(39) 0.02336 
ARTHRALGIA  65%(79) 63%(45) 67%(35) 0.0288 
ABDOMINAL PAIN 57%(69) 46%(33) 71%(36) 0.0097 
NAUSEA/VOMITING 59%(72) 51%(36) 71%(36) 0.0397 
ALTERED BOWEL 
MOVEMENTS 30%(37) 18%(13) 47%(24) 0.0012 
CORYZA  52%(64) 54%(38) 51%(26) 0.8549 
SLEEPLESSNESS/ 
LETHARGY  57%(70) 44%(31) 75%(39) 0.0004 
       
 
Past History of  viral fever within 2yrs was present in around 27(22%) pts. Among 
which, 17(33%) had DHF, Which is statistically significant (p=0.0553). 
General and systemic examination findings were noted except bleeding and plasma 
leakage manifestations. 
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Table 5. Clinical signs 
SIGNS Total 
n=122 
DF 
n=71 
DHF 
n=51 P value 
LYMPHADENOPATHY 31%(38) 23%(16) 44%(22) 0.0183 
FACIAL FLUSH 39%(36) 10%(7) 57%(29) 0.0001 
CONJUNCTIVAL 
INJECTION 47%(57) 35%(25) 63%(32) 0.0033 
HEPATOMEGALY 11%(13) 8%(6) 14%(7) 0.3849 
SPLENOMEGALY 15%(18) 13%(9) 18%(9) 0.4518 
ENCEPHLOPATHY 2.5%(3) - - - 
 
 Conjunctival injection, Facial flush and Lymphadenopathy occurred among  statistically 
significant population with DHF. 
Dengue Encephalopathy occurs in 3(2.5%) patients.  
LAB PARAMETERS 
 Complete Haemogram, Liver function tests, Renal function test, electrolytes and Chest 
X-ray were done. Only Haemogram and Liver function test results were showed abnormal 
values. These investigations were analyzed. Other investigations were mostly within normal 
limits.   
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Table 6. Complete Blood Count 
CBC Total 
n=122 
DF 
n=71 
DHF 
n=51 P value 
TC <3,500 17%(21) 15%(11) 19%(10) 0.6296 
TC > 11,000 13%(16) 11%(8) 16%(8) 0.5886 
EOSINOPHIL >8% 21%(26) 11%(8) 35%(18) 0.0018 
HAEMATOCRIT  > 
45% 20%(24) 14%(10) 27%(14) 0.1047 
  
Liver enzymes  
Mean SGOT in DHF : 126  IU 
 Mean SGPT in DHF :  108 IU 
Elevation of Liver enzymes in DHF is statistically significant. 
Table 7. Liver Enzyme levels 
LFT Total 
n=122 
DF 
n=71 
DHF 
n=51 P value 
SGOT >40IU 52%(64) 31%(22) 78%(40) 0.0001 
SGOT 
>100IU 26%(32) 6%(4) 55%(28) 0.001 
SGPT >40IU 39%(47) 13%(9) 75%(38) 0.0001 
SGPT >100IU 22%(27) 4%(3) 47%(24) 0.0001 
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THROMBOCYTOPENIA  
 Around 51 (42%) patients had platelet count less than 1,00,000. 
Table 8. Thrombocytopenia and Platelet Count Distribution 
PLATELET COUNT PERCENTAGE  (n=122) 
<1,00,000 42% (51) 
PLATELET COUNT 
DISTRIBUTION PERCENTAGE(n=51) 
1,00,000 – 80,000 20% (10) 
79,000 – 60,000 17% (9) 
59,000 – 40,000 25% (13) 
39,000 – 20,000 24% (12) 
19,000 – 10,000 8% (4) 
< 10,000 6% (3) 
  
  Mean platelet count in thrombocytopenic patient was 47,176 platelets/mm3. 
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HAEMORRHAGIC MANIFESTATIONS 
 Total No of patients with Bleeding manifestations : 42% (51) 
  Table 9. Haemorrhagic manifestations 
BLEEDING MANIFESTATION OCCURRENCE (n=51) 
EPISTAXIS 16% (8) 
MALENA 47% (24) 
HAEMATEMESIS 39% (20) 
BLEEDING GUMS 35% (18) 
RASHES 67% (34) 
VENAE PUNCTURE BLEED 61% (31) 
HESS TEST 8% (4) 
OTHERS 3.6% (7) 
 
 Rashes and Venae puncture Bleeding were common bleeding manifestations. But overall 
GI bleeding was most common. 
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PLASMA LEAKAGE MANIFESTATIONS 
 Total No of patients with Plasma Leakage  manifestations : 42% (51) 
  Table 10. Plasma leakage manifestations 
PLASMA LEAKGE 
MANIFESTATION OCCURANCE (n=51) 
PLEURAL EFFUSION (PE) 
84% (43) 
RIGHT PE – 62% (27) 
LEFT PE – 18% (8) 
BILATERAL PE – 20% (9) 
ASCITES 88% (45) 
GALL BLADDER WALL 
OEDEMA 10% (5) 
INCREASED HAEMATOCRIT 27% (14) 
HYPOPROTEINEMIA 20% (10) 
HYPOTENSION 26% (11) 
 
 Ascites & Pleural effusion were common Plasma leakage manifestations. All cases of 
pleural effusion and Ascites were detected by USG examination.  
 All patients with Gall Bladder wall edema were affected with severe Dengue Infection. 
So Gall bladder wall edema is a significant finding to detect DHF. 
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OUTCOME 
 DF patients were treated with paracetamol and close observation for complications for at 
least two days to detect complications. 
 All DHF – II (35) patients were started with IV fluid at the rate of 6-7 ml/kg/hr with 
5%DNS. If patient maintained a stable BP,  the fluid infusion rate was reduced to 3-4 ml/kg/hr. 
Vitals, Platelet count  and Haematocrit were scrutinized regularly and managed according to the 
state of BP. No patients developed hypotension or mortality.2 patients had platelet count < 
20,000 with bleeding, they were treated with 4unit Platelet concentrate.  
 Of the 12 patients with DSS 10 were treated in IMCU of Stanley Medical Hospital. 2 
patients were managed in medical ward itself. Those 2 patients were managed only with IV 
crystalloids.  
 Patients with DHF – III (9) were carefully monitored for changes in Blood pressure. 
Patients were treated with 5%DNS in the rate of 6-7ml /kg/hr. 4 patients did not improve with 
this treatment. Then the infusion rate was increased to 10 ml/kg/hr and then to 15 ml/kg/hr. With 
this treatment 2 patients improved. But 2 patients remained hypotension. Their PCV was 
investigated and after confirmation of its elevated value, the patients were infused with 4packs of 
FFP (fresh Frozen Plasma) each. Both of them improved after 1 day. Among 9 patients, 2 pts had 
platelet <20,000. They were  treated with 4 unit of platelet concentrate. Mortality of the 4 
patients was prevented by timely measures against hypotension and thrombocytopenia. One 
patient had low haematocrit, in who was transfused with whole blood. 
 DHF – IV (3) patients were treated with IV crystalloids at 20ml/kg/hr. 2 patients had 
profound bleeding. Both patients were treated with platelet transfusion. Two patients were 
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recovered with IV fluid therapy and platelet transfusion. But one patient developed severe 
thrombocytopenia and low haematocrit. Around 6 units of platelets was transfused. 3unit of 
whole Blood were transfused. Even with this effective management in IMCU, bleeding didn’t 
get arrested. Shock could not be corrected. Patient expired with intractable shock. 
Fresh frozen Plasma given for  : 2patient 
Platelet concentrate given for   : 7patients 
Blood transfusion given for   : 2patients  
 
Case Fatality Rate (CFR)   : 0.008% 
 
 Around 12 patients (DSS) were in a critical condition, but improved with effective 
treatment. Only one patient expired, due to intractable shock. 
   
  
 
 
 
 
  
 
 
DISCUSSION 
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DISCUSSION 
 
 In India, 5,534 cases of Dengue were reported in 2007 with 80deaths. In 2008, 12,419 
cases of Dengue were reported with 69deaths. Case Fatality Rate was 0.6%. In 2006, Tamilnadu 
contributed to 4% cases, most of which were from Chennai. Researchers are considering these 
datas as only tip of the iceberg of the actual situation. Most Dengue clinical studies were done in 
paediatric age group. Adult studies are quite limited, especially in India. 
 This present study was done in Stanley Medical College Hospital, North Chennai, which 
is highly endemic for most infectious diseases. As Dengue fever is one of the common infectious 
diseases, the incidence is relatively high in North Chennai. Most Dengue cases were managed as 
OP which is commonly presenting as simple viral illness in adults. In this study, we have taken 
into consideration only those who were admitted cases in Medical ward. 
 Here, we want to analyse present study by comparing with other Dengue adult studies. 
Indian and other South Asian region studies are taken up for the discussion. 
 Total of 122 cases of Dengue infection admitted to Stanley Medical college Hospital 
were analysed. Dengue Fever (DF) occurred in 71(58%) patients. Dengue Haemorrhagic Fever 
(DHF) occurred in 51 (42%) patients. Among patients with DHF around 3(2%) patients 
developed suffered with Dengue Shock Syndrome (DSS). 
Dengue infection commonly occurred in Males (66%). M: F ratio is 1.9:1. Mean age was 
29 ± 13.5 yrs. Majority of patients around 65%, were in the Age group of 13 – 30 yrs. 
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 Among Dengue infections, DHF occurred in 42% of cases. DHF commonly presented in 
the Age group of 13 – 30 yrs, same as Dengue Infection. Elderly Patients were not affected with 
DHF. Mean Age was 29 ± 11yrs. 63% were males. M: F ratio was 1.7:1. 
Parameters 
Present 
study 
n=122 
Malavige et al 
Srilanka42 
n=108 
NPSingh     
et al 
Delhi44 
n=185 
Janak 
Kishore et 
al; 
Lucknow45 
n=100 
Adriana O 
et al; 
Brazil43n=185 
DF 58% 30.6% - 46% - 
DHF 42% 69.4% - 54% - 
Mean Age 29±13.5yrs 26.6yrs 26±10yrs 30±14yrs 32±12yrs 
Age 
Distribution 13-40yrs 13-56yrs 12-29yrs 15-30yrs - 
M:F 1.9:1 1.4:1 3:1 2:1 1.7:1 
 
 Most of the other Dengue studies were comparable with present study. In other studies 
the incidence of DHF is more than 50%, where most of the patients were admitted for 
complications by referrals. Age – Sex Distribution, Mean age and Male: Female ratio of the 
other studies was equally comparable with our studies. 
 Malavige et al & Adriana et al studies show the primary infection occurs in 34% patients, 
whereas present study shows it to be 24%. 
 In present study, the incidence of cases was mostly during the period of September 2007 
to January 2008. The incidence reduced drastically in 2008 compared to 2007. This decline in 
incidence may be explained by effective step of the Government via mosquito control 
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programme in 2008, after the high incidence of Dengue fever in 2007. Seasonal distribution of 
case incidence corresponds mostly to the period of August to December in both years. This same 
Seasonal pattern was classically reported by WHO for Indian Seasonal Pattern of Dengue 
Infection for 2003 – 2006.   
 
Present study 
n=122 
Malavige et al 
Srilanka42 
n=108 
Janak Kishore 
et al; 
Lucknow45 
n=100 
Adriana O 
et al; 
Brazil44 n=185 
DHF 42% (51)   23% 
DHF I & II 76% 81% 76% 74.4% 
DHF III & IV 24% 19% 24% 25.6% 
  
The incidence of Dengue Haemorrhagic Fever (I & II) & DSS (III & III) are similar with 
other adult studies. In all studies including presnt study, DHF -II was common type. 
CLINICAL FEATURES: 
 Fever has been documented 100% in all adult Dengue studies including present study. 
The average duration  
 
Present study 
n=122 
Malavige et al 
Srilanka42 
n=108 
Janak Kishore 
et al; 
Lucknow45 
n=100 
NP Singh     et al 
Delhi44 
n=185 
Average Fever 
Duration 
4.9 ± 1 days 4.7 days 5.9 days 4.5 ± 1 days 
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 In all studies, including Present study high grade & continuous fever were commonly 
recorded. The average duration of fever is also nearly same. 
Parameters 
Present 
study 
n=122 
Malavige et al 
Srilanka42 
n=108 
NP Singh     
et al 
Delhi44 
n=185 
Janak Kishore et 
al; 
Lucknow45 
n=100 
Headache 77% 66% 61.6% 17% 
Myalgia 82% 76% 57.8% 18% 
Arthralgia 65% 57% - 21% 
Vomiting/ 
diarrhea 59% 63% 50% 16% 
Abdominal pain 57% 16% 21% - 
 
 These common symptoms of Present study were comparable with other adult Dengue 
studies. Abdominal pain was more common in Present study when compared with other studies. 
But abdominal pain was common in DHF than DF in all studies including Present study and the 
p value of Present study is significant for DHF. 
 Past History of viral illness was commonly recorded in DHF than DF. This past history 
was not analysed in other studies. In Present study, around 22% patients had viral illness in the 
recent past. 
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Parameters 
Present 
study 
n=122 
Malavige et al 
Srilanka42 
n=108 
pradeep  et al 
 
Janak Kishore et 
al; 
Lucknow45 
n=100 
Lymphadenopathy 37% - 26% - 
Facial flush 30% 42% 42% 53% 
Hepatomegaly 11% 45% 45% - 
Spleenomegaly 15% 2.7% 13% - 
   
 Lymphadenopathy was not studied in most studies. In the Present study 
lymphadenopathy occurred significantly in DHF. Other clinical parameters occurred in the lower 
percentage in Present study when compared to other studies. 
LAB PARAMETERS 
 Elevated liver enzymes were commonly studied in paediatric studies. In Present study 
SGOT & SGPT were elevated to statistically significant levels in DHF as compared to DF.  
Parameters 
Present 
study 
n=122 
NP Singh et al 
Delhi44 
n=185 
Janak Kishore et al; 
Lucknow45 
n=100 
SGOT >40 IU 52% 16% 48% 
SGPT >40 IU 39% 17% 49% 
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 Janak Kishore et al study shows the elevation of liver enzymes, similar to Present study.  
 
 
THROMBOCYTOPENIA 
Thrombocytopenia 
Present 
study 
n=122 
Malavige et 
al 
Srilanka42 
n=108 
NP Singh     
et al 
Delhi44 
n=185 
Janak 
Kishore et 
al; 
Lucknow45 
n=100 
Adriana O 
et al; 
Brazil43 
n=185 
Total 42% 74% 61% 70% 70% 
Mean platelet count 
in DHF 47,176 - 66,000 43,210 - 
 
 Thrombocytopenia was the most commonly studied parameter in previous Dengue 
studies. Other clinical features need to be monitored when the patient suffered from DHF, with 
plasma leakage manifestations. 42% patients had thrombocytopenia in Present study. Mean 
platelet count was 47,176 cells/mm3. Around 49% patients had platelet count between 20,000 – 
60,000 cell/mm3. Only 6% patients had platelet count less than 10,000cells/mm3. 
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HAEMORRHAGIC MANIFESTATION 
Bleeding 
manifestation 
Present 
study 
n=122 
Malavige et al 
Srilanka42 
n=108 
NP Singh     et al 
Delhi44 
n=185 
Total 42% 39% 40% 
Epistaxis 16% 24% 14% 
Malena 47% 34% 16% 
Bleeding gums 35% 17% - 
Hematemesis 37% 40% 22.2% 
Rashes 67% 54% 31.9% 
Venae puncture bleed 61% - - 
Hess test 8% - 21% 
 
 In Present study, rashes, Venae puncture Bleed, Malena and Hematemesis were the 
common bleeding manifestations. Malavige et al study describes rashes and hematemesis as 
common bleeding manifestations. In all other studies rashes were predominant bleeding 
manifestations. 
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PLASMA LEAKAGE MANIFESTATIONS 
Plasma Leakage 
manifestation 
Present 
study 
n=122 
Malavige et 
al 
Srilanka42 
n=108 
NP Singh     
et al 
Delhi44 
n=185 
Adriana O 
et al; 
Brazil43 
n=185 
Total 42% 74% 61% 70% 
Pleural Effusion 84% 16% 2% 56% 
Ascites 88% 17% 2% 56% 
Increased 
Haematocrit 27% 26% 5.6% - 
Hypotension 26% 18% - 26% 
 
 In Present study, Ascites & Pleural Effusion played a major role in diagnosis of DHF. 
Hypotension occurred in 26% patients. In other studies the plasma leakage manifestations were 
limited. Plasma leakage, manifestations  very difficult to diagnose clinically except Hypotension. 
So in most studies hypotension was the common plasma leakage manifestation. Recognition and 
early IV fluid therapy for hypotension is necessary. 
 Past history of previous similar viral illness present in 22% in total of 122 patients. 
Among patients with DHF past history of fever was present in 33% cases. 
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 Gall bladder wall edema is a marker for DHF, was present in 5 patients of the present 
study. 
 Encephalopathy occurred in 3 patients. All the patients had fever for 2-3 days, followed 
by altered level of consciousness and acute confusional state. The confusional state recovered 
over 2-3 days. No focal neurological deficit had been demonstrated. Metabolic state, CSF 
analysis and Imaging were normal in all 3 patients. They were all are positive for dengue card 
test along with clinical features of Dengue fever.  
 One 14yr old boy expired in Present study due to intractable Dengue Shock Syndrome. 
Case fatality rate was 0.0008% in present study. But in other studies it was high. 
  
STUDY CASE FATALITY RATE 
Present study (n=122) 0.008% 
Malavige et al; Srilanka42 (n=108) 3.7% 
NP Singh et al: Delhi44 (n=185) 2.7% 
Harris et al46 0.001% 
Kulatate et al47 0.02% 
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 The mortality varies in many studies. Most of the studies were hospital based studies in 
which the hospital admissions were individual based and the mortality is largely prevented my 
effective management in hospital. So recognition of early haemorrahgic fever and special 
medications like FFP, Platelet concentrate and whole Blood act as cornerstone of management of 
complications.    
 In present study platelet concentrate were given for 7 patients, FFP for 2 patients and 
Whole Blood transfusion for 2 patients. The transfusion rate was low in present study compared 
to other studies. In Malavige et al study it was 12%, which is done in Srilanka. So effective early 
recognition and management of complications markedly decreases mortality. 
 
 
 
 
 
 
 
 
 
 
  
 
SUMMARY 
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SUMMARY 
1. Dengue fever occurred in 122 patients in present study. 42% patients had DHF. DHF-II 
was common type of DHF. 
2. Dengue Shock syndrome occurred in 9% patients. 
3. DF as well as DHF commonly occurred in the age group of 13 – 30 yrs  
4. Mean Age – 29 ± 13.5 yrs; males (66%) were commonly affected than female; M : F is 
1.9 : 1. 
5. Most of the Dengue infection occurred during the period of October to January of the 
year. 
6. Secondary infection (76%) was common compared to primary infection (24%) especially 
among DHF. 
7. Other than Fever (100%) Myalgia (82%), arthralgia (65%) and Headache (77%) were 
common symptoms described in present study. 
8. Abdominal symptoms, Sleeplessness/ lethargy, facial flushing and conjunctival injection 
occurred significantly in DHF than DF. 
9. Elevated Eosinophil count and Transaminases occurred in DHF than DF. 
10. Thrombocytopenia, Haemorrhagic manifestations and Plasma leakage manifestations 
occurred in 42% patients. 
11. Rashes (67%), Venaepuncture bleed(61%) and Malena (47%) were common bleeding 
manifestations. 
12. Ascites (88%) and Pleural Effusion (84%) were common plasma leakage manifestations. 
13. Hypotension occurred in 26% patients. All patients were treated with IV fluid according 
to WHO protocol. 
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14. IV crystalloids were the primary modality of treatment in patient with DHF. According to 
the guidelines Whole blood transfusion (2patients), FFP (3patients) and Platelet 
concentrate (4patients) were also given for DSS. 
15. All DHFs  were diagnosed early with appropriate investigations and managed effectively 
with transfusions and IV crystalloids. These effective measures saved 11 DSS patients 
except one. 
16. One patient expired. Case Fatality Rate was 0.008%. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
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CONCLUSION 
 
A total 0f 122 cases with Dengue were analysed. Results show that Dengue fever and 
Dengue haemorrhagic fever were noted in adults particularly during epidemics. Fluid Therapy is 
the corner stone of management in Dengue Haemorrhagic fever. Early recognition and 
aggressive management of complications is essential to prevent mortality in adults.
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PROFORMA 
Name:   
Age:   Sex:   I.P.No:   DOA:  
Symptoms: 
Fever:    Days:  Days prior to admission:  High/Low 
Continuous/Intermittent     Chills: 
Headache:   Days:  Area: 
Retro orbital Pain:  Myalgia: Arthralgia: 
Hemorrhagic manifestations: 
Epistaxis/ malena/ Gum bleed/ Hematemesis/ Vena.Punc.Bleed/ Hess Test/ Rashes(area:          )/ 
other- menorrhagia, prolonged bleed 
 
Abdominal Pain:   Nause/Vomiting:   Constip/Diarrhea: 
Coryza:     Sleep/Lethargy:   Past h/o fever 
BP 
Pulse rate: 
 
Temp; <39/>390 :   Palor:      Face\flush: 
Conj.Injection:    Lyphadenopathy:    Systemicexamination 
 
Laboratory Investigations: 
TC   DC-N   DC-L   DC - E   PCV   HB  Platelet 
BT   CT   Sugar   Urea    Crea   S.Bil SGOT 
SGPT   SAP   T.Protein  S.Alb 
Dengue Test    IgM:    IgG: 
CXR 
USG Abdomen: 
Blood transfusion: 
FFP transfusion 
Platelet transfusion: 
Dengue :Infection Type: Primary?secondary   Dengue Type: DF/DHF/DSS 
        Grade of DHF:I/II/III/IV 
Outcome: 
 
 
 
S. No Name Age Sex IP No DOA Occupation Address Fever Days Gap to admission H/L Chills Day/Ni Headache Days Area ROP Myalgia
1 Aravind 14 1 421342 28/8/07 student vanarpaettai 1 4 2 h 1 i 1 2 f 1 1
2 saritha 24 f 39079 28/8/07 hw chennai 1 10 6 1 0 1 0 0 0 0 1
3 ravi 40 1 39124 20/11/07 driver achara 1 7 4 h 0 i 1 3 f,p 0 0
4 thomas 20 1 29475 2/9/2007 shopper chennai 1 5 2 h 1 b 1 2 f 1
5 Radha 43 1 41307 11/12/2007 farmer padi 1 3 2 h 0 i 1 2 f 0 0
6 Baskaran 23 1 32123 22/9/08 student chennai 1 5 3 h 1 b 1 3 p,t 0 1
7 Sathish 17 1 31995 21/9/08 colley chennai 1 7 2 1 1 b 1 4 p,t 0 1
8 Velmurugan 18 1 32667 25/9/07 student chennai 1 3 1 h i 0 0 0 0 1
9 Premalatha 19 f 32286 23/9/07 student chennai 1 3 1 h 0 i 1 1 f,t 0 1
10 soniya 19 f 32189 22/9/07 student chennai 1 4 1 h 1 b 0 0 0 0 1
11 Vignesh 15 1 33305 1/10/2007 student chennai 1 8 3 h 1 b 1 5 p,t 0 1
12 Asokan 25 1 34618 11/10/2007 driver thiruthani 1 4 2 h 0 1 1 2 f,t 0 1
13 Mohan 19 1 35140 16/10/2007 mechanic pudhukuppam 1 7 5 h 0 b 0 0 0 0 1
14 Raghu 50 1 35141 16/10/07 farmer thiruthani 1 6 4 h 1 1 1 2 f,t 0 1
15 Shanthy 35 f 35236 16/10/07 hw chennai 1 7 5 1 0 i 1 5 f,t 0 1
16 Mallika 42 f 35222 16/10/07 hw chennai 1 8 4 h 1 b 1 3 f 0 1
17 Selvi 19 f 34997 15/10/07 hw chennai 1 6 3 h 1 b 1 3 f 0 1
18 Yasodha 70 f 35003 15/10/07 cooly thiruvani 1 4 3 1 1 1 0 0 0 0 1
19 Parvathy 40 f 34970 23/10/07 hw chennai 1 5 3 h 0 b 0 0 0 0 0
20 Bakiyalakshmi 42 f 35093 15/10/07 hw chennai 1 3 2 1 0 i 0 0 0 0 0
21 Maran 22 1 35607 19/10/07 farmer vellore 1 5 2 1 1 b 1 3 all 0 1
22 Sankar 30 1 36055 23/10/07 road work ponndamalee 1 8 4 h 1 b 1 3 all 0 1
23 Babu 30 1 36079 23/10/07 cooly chennai 1 5 3 1 0 i 1 4 occ 1 1
24 Shanker 23 1 36020 24/10/07 cooly chennai 1 5 2 h 1 1 1 3 f 1 0
25 Rajesh kumar 16 1 36026 23/10/07 student chennai 1 6 3 h 1 i 1 3 f 0 1
26 Prasanth 14 1 36121 24/10/07 student chennai 1 6 3 1 1 1 1 3 f,o 0 1
27 Jothi 28 1 1/11/2007 driver tiruvan 1 6 4 h 1 i 0 0 0 0 1
28 Ramesh 32 1 38969 19/11/07 shopper padi 1 4 2 h 0 1 1 2 f,t,o 0 1
29 Mani 60 1 39692 26/11/07 painter chennai 1 4 2 h 0 1 1 2 f 0 1
30 Gnanaprakasam 73 1 39733 26/11/07 cooly chennai 1 3 1 h 1 1 1 1 f,t 0 1
31 Arunkumar 15 1 39839 27/11/07 student chennai 1 6 3 1 1 i 0 0 0 0 0
32 Anandhan 37 1 41842 27/11/07 mason chennai 1 5 3 h 1 b 1 3 f 0 1
MASTER  CHART
33 Aseemdoss 20 1 40 1/1/2008 colley chennai 1 6 4 1 0 b 1 3 occ 1 1
34 Krishnakumar 19 1 88 1/1/2008 shopper chennai 1 6 3 h 1 i 1 3 f 1 1
35 Indirani 45 f 347 2/1/2008 hw chennai 1 5 2 1 0 1 0 0 0 0 0
36 Mohamad Haniff 45 1 56431 4/12/2007 worker chennai 1 3 2 h 1 1 1 2 occ 0 1
37 Vijayan 18 1 32944 29/12.07 rikshaw chennai 1 5 4 h 1 1 1 4 f 0 1
38 Praveen kumar 13 1 33144 29/9/07 student kasimedu 1 6 4 h 1 1 0 0 0 0 1
39 Vijayababu 22 1 33036 28/12/07 farmer thiruthani 1 5 3 h 0 i 1 2 occ 1 1
40 Kumar 22 1 33728 21/10/07 shopper chennai 1 3 1 h 0 1 1 2 f 0 1
41 Vinoth 21 1 33614 4/10/2007 student chennai 1 3 1 h 0 1 1 2 f,t 1 1
42 Vimalraj 19 1 33532 3/10/2007 farmer tiruporur 1 4 3 1 1 i 1 2 f,t 0 0
43 Dessapan 19 1 33779 6/10/2007 rikshaw chennai 1 6 4 h 1 i 0 0 0 0 1
44 Meyal Joy 33 1 34052 10/12/2007 student chennai 1 3 1 h 1 1 1 3 0,f,t 1 1
45 Venkataesen 23 1 42423 12/12/2007 cooly chennai 1 6 3 1 1 i 1 2 o,f 0 1
46 Sindhu 27 f 42563 16/12/07 hw chennai 1 7 4 1 0 i 1 3 f,t 0 1
47 Anbu 40 1 43423 28/12/07 driver chennai 1 7 4 h 1 i 0 0 0 0 1
48 Usha 24 f 36737 30/11/07 hw chennai 1 6 3 h 1 i 0 0 0 0 0
49 Ramanammal 70 f 36816 30/11/07 hw chennai 1 4 2 h 0 1 1 2 all 0 1
50 Vasanthi 14 f 37063 1/11/2007 hw chennai 1 4 2 h 0 1 1 2 f,t 0 1
51 jaya 26 f 36395 11-Mar hw chennai 1 6 3 h 0 i 1 5 f 0 1
52 Kanniammal 37 f 37063 11-Mar hw chennai 1 5 2 h 1 i 0 0 0 0 0
53 Vasudevan 25 1 36862 31/11/07 shopper chennai 1 4 3 1 0 i 1 3 f 1 1
54 Subhashini 35 f 37538 5/12/2007 hw chennai 1 6 2 h 0 1 1 4 all 1 1
55 Rajaesh 19 1 38121 12/12/2007 student chennai 1 6 2 h 0 1 1 4 all 0 1
56 Sundar 32 1 2179/08 22/1 shopper chennai 1 6 4 1 1 i 0 0 0 0 1
57 Syed umar 15 1 1213 11/1/2008 student chennai 1 5 3 h 1 i 1 2 all 0 0
58 Guna 19 f 33368 2/11/2007 student chennai 1 4 2 h 1 i 1 3 all 0 1
59 Yamuna 34 f 33348 21/12/07 hw chennai 1 4 2 h 0 1 1 3 f 0 1
60 Tamilarasi 20 f 24118 24/2/08 hw chennai 1 6 4 1 1 i 0 0 0 0 0
61 Mareeswari 18 f 33334 5/3/2008 student chennai 1 3 1 h 1 1 1 2 f 0 0
62 Sharmila 25 f 37393 5/3/2008 hw chennai 1 4 2 h 0 1 0 0 0 0 0
63 Maheswari 19 f 37950 10/3/2008 student chennai 1 3 1 h 0 1 1 2 f 0 1
64 Pugazathi 30 f 38584 12/3/2008 hw chennai 1 4 2 h 1 i 1 2 f 0 1
65 Kalaivanan 20 1 11172 7/9/2008 student chennai 1 3 1 h 0 1 0 0 0 1 1
66 Raziyabee 42 f 37435 8/10/2008 hw chennai 1 3 1 h 0 1 1 2 0 0 0
67 Munusamy 40 f 37435 16/11/08 farmer tirutani 1 6 4 h 1 i 1 2 occ 1 0
68 Anadhanarayanan 21 1 38386 15/9/08 mason chennai 1 4 2 h 0 1 1 2 f 1 1
69 sundar 20 1 32453 9-Jul cooly chennai 1 6 4 1 0 i 1 2 f 0 1
70 Vanitha 25 f 34733 12/9/2008 hw chennai 1 3 1 h 0 1 0 0 0 0 0
71 Kannan 28 1 34784 15/9/08 cooly chennai 1 4 2 h 0 1 0 0 0 0 0
72 Saranraj 19 1 34822 17/9/08 student chennai 1 5 2 1 0 i 1 1 all 0 0
73 Soniya 21 f 35207 20/9/08 student chennai 1 3 2 h 1 1 1 2 all 0 1
74 satheeshvaran 15 1 36162 25/9/08 student chennai 1 5 3 1 1 i 1 2 all 0 1
75 Lakshmi 45 f 33336 6/9/2008 hw chennai 1 5 3 h 0 i 1 4 all 0 1
76 Ranjitham 48 f 1/10/2008 hw chennai 1 3 1 h 0 1 1 2 f 0 1
77 Kasthuri 45 f 33306 3/10/2008 hw chennai 1 6 3 h 0 i 1 2 f 0 1
78 Udhaya reagen 24 1 33408 1/10/2007 electrician chennai 1 7 3 1 1 i 1 2 o 0 1
79 Suresh 28 1 33455 3/10/2008 cooly chennai 1 6 4 1 1 i 1 3 all 0 1
80 Srinivasan 40 1 43224 6/1o/08 cooly chennai 1 4 1 h 1 1 1 3 all 0 1
81 Saravanan 14 1 33970 8/10/2007 student chennai 1 3 3 h 0 1 1 3 all 0 1
82 Lakshmi 26 f 326002 2/11/2007 hw chennai 1 6 3 1 0 i 1 3 f 0 1
83 Ashnaf 23 1 35407 13/10/07 hw chennai 1 3 2 h 0 1 1 2 f 0 1
84 Mohamed Hussain 16 1 34763 13/10/07 hw chennai 1 4 2 h 1 1 1 2 f,o 0 1
85 Bakyalakshmi 23 f 33829 5/10/2007 hw chennai 1 3 1 h 1 1 0 0 0 0 1
86 Rajesweri 13 f 34024 6/10/2007 student chennai 1 4 1 h 0 1 1 2 a 0 1
87 Ramadevi 19 f 34192 7/10/2007 student chennai 1 4 2 h 1 1 0 0 0 0 1
88 Deepa 19 f 35876 22/10/07 student chennai 1 3 2 h 1 1 0 0 0 0 1
89 Sivagami 40 f 35287 17/10/07 hw chennai 1 3 2 h 0 1 1 2 a 0 1
90 Anand 20 1 40344 3/12/2007 shopper chennai 1 4 2 h 0 1 1 2 a 1
91 Mohamed Iqbal 20 1 40611 5/12/2007 business chennai 1 4 2 h 1 i 1 2 a 0 0
92 Annadurai 36 1 40637 5/12/2007 colley chennai 1 4 3 h 0 i 1 2 a 0 1
93 Suresh 27 1 40841 6/12/2007 labour chennai 1 4 2 1 1 i 1 2 a 0 1
94 Thangaraj 16 1 40976 9/12/2007 student chennai 1 6 4 1 1 i 1 4 a 0 1
95 Durai 55 1 41190 11/12/2007 labour chennai 1 6 3 1 0 i 1 3 f 0 1
96 Goutham shanker 20 1 41115 10/12/2007 student chennai 1 6 3 1 0 i 1 2 a 0 1
97 Dhanasekaran 13 1 41166 10/12/2007 student chennai 1 7 4 1 0 i 1 2 a 0 1
98 Lisban 49 1 41361 10/12/2007 shopper chennai 1 2 2 h 0 1 0 0 0 0 1
99 Devamoorthy 29 1 41701 16/12/07 farmer manali 1 6 4 1 0 i 1 2 o 0 0
100 Harikrishnana 15 1 41956 18/12/07 student chennai 1 6 4 1 1 i 1 2 o 0 1
101 Allirajan 32 1 42013 17/12/07 driver chennai 1 5 3 1 0 i 1 4 a 0 1
102 Munivel 25 1 42314 19/12/07 labour chennai 1 7 4 1 1 i 1 5 0 1
103 Paneerselvam 52 1 42346 20/12/07 labour chennai 1 5 3 h 1 1 1 3 a 0 1
104 Vijaya 30 f 42619 25/12/07 hw chennai 1 6 3 h 0 1 1 3 a 1 1
105 Jothy 40 1 42655 27/12/07 shopper chennai 1 7 4 1 1 i 1 4 o 0 1
106 Antony 65 1 42953 30/12/07 farmer chennai 1 3 2 h 1 1 1 2 o 0 1
107 Harikrishnan 43 1 32145 31/11/07 labour chennai 1 4 3 1 1 1 1 3 f 0 1
108 Thirumal 19 1 638 4/1/2008 student chennai 1 4 2 h 1 1 1 2 a 0 1
109 sharmila 18 f 34506 11/10/2007 student chennai 1 3 2 h 0 1 0 0 0 0 1
110 chithra 26 f 38395 11-Mar hw chennai 1 6 3 h 0 i 1 5 f 0 1
111 kuppan 15 1 32305 1/10/2008 student chennai 1 8 3 h 1 b 1 5 p,t 0 1
112 Balu 37 1 41842 27/11/08 mason chennai 1 5 3 h 1 b 1 3 f 0 1
113 Saravanan 23 1 35407 13/10/08 hw chennai 1 3 2 h 0 1 1 2 f 0 1
114 seetha 30 f 38584 12/3/2008 hw chennai 1 4 2 h 1 i 1 2 f 0 1
115 Tirupathi 40 1 42635 27/12/08 shopper chennai 1 7 4 1 1 i 1 4 o 0 1
116 Sundar 32 1 32412 22/1/08 shopper chennai 1 6 4 1 1 i 0 0 0 0 1
117 Moorthy 40 1 68435 16/11/08 farmer tirutani 1 6 4 h 1 i 1 2 occ 1 0
118 Vedhan 18 1 32237 25/9/08 student chennai 1 3 1 h i 0 0 0 0 1
119 Sooranammal 70 f 36216 30/11/08 hw chennai 1 4 2 h 0 1 1 2 all 0 1
120 prbakaran 40 1 46224 6/1o/08 cooly chennai 1 4 1 h 1 1 1 3 all 0 1
121 Mayilsamy 22 1 33607 19/10/08 farmer vellore 1 5 2 1 1 b 1 3 all 0 1
122 Sandha kumar 37 1 41842 27/11/08 mason chennai 1 5 3 h 1 b 1 3 f 0 1
Arthralgia Hemorrhagic Epistaxis malena Gum bleed Hematemesis Vena.Punc.Bleed Hess Test Rashes Rashes Area Abdominal Pain Nause/Vomiting Constip/Diarrhea
1 1 1 0 1 1 0 1 1 1 0
1 1 1 1 1 legs,arms,back 1
0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 1 0 0 1 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 1 0 0
1 1 0 0 0 0 1 0 1 0 1 0 0
0 0 0 0 0 0 0 0 0 0 1 1 0
0 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 1 1 0
1 1 0 1 1 1 1 0 1 trunk 1 1 1
1 0 0 0 0 0 0 0 0 0 0 1 0
1 1 0 1 1 0 0 0 0 0 1 0 0
1 1 0 0 0 1 1 0 1 trunk 0 1 0
1 1 1 1 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 1 0 1 trunk 1 0 0
1 1 0 1 0 1 1 0 1 body 1 1 1
1 1 0 0 0 1 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 0 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 0 1 1
1 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 1 1
0 1 1 0 0 0 0 0 1 sub conj 0 1 1
1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 0 1 1 1 1 1 0 1
1 1 0 1 0 1 0 1 1 chest,back 1 1 1
0 1 1 0 0 1 1 0 0 0 0 1 1
1 1 0 0 1 0 0 0 1 limbs,chest 1 1 1
1 1 0 0 1 1 0 0 1 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 1 1 1 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0
0 1 0 0 0 0 0 0 1 back ,leg 0 0 0
1 0 0 0 0 0 0 0 0 0 0 1 1
0 0 0 0 0 0 0 0 0 0 0 0 1
1 1 0 1 0 1 0 0 0 0 1 1 0
1 1 1 1 1 0 0 0 1 forarm,leg 1 1 0
1 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 1 0
1 1 0 1 0 1 1 1 1 sub conj,back 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 1 1 0 0 0 1 trunk 1 0 0
1 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 1 0 1 0 1 hands 1 1 1
0 1 0 0 0 0 1 0 1 legs,arms,back 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 1 0
1 1 0 1 1 0 1 0 1 legs,arms,back 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 0 1 0 1 arms,legs 1 0 0
1 1 0 1 1 1 1 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 1 0
0 1 0 0 0 0 1 0 1 0 0 0 0
1 1 0 1 0 1 0 0 1 0 1 1 1
0 1 1 0 1 0 0 0 0 0 1 1 1
0 1 0 0 0 0 1 0 1 0 0 1 1
1 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 1 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 1 1 1 1 1 1 1 all over 1 1 0
0 1 0 1 0 1 0 0 0 0 1 1 0
1 1 0 0 0 0 1 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 1 1 0
0 1 0 1 0 0 1 0 1 0 1 0 0
1 1 0 0 0 0 0 0 1 trunk 1 1 0
0 0 0 0 0 0 0 0 0 0 0 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 1 0 0
0 0 0 0 0 0 0 0 0 0 0 1 0
0 1 0 1 1 0 1 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 1 1 0
1 1 0 0 0 0 0 0 1 arms,legs 1 1 0
0 0 0 0 0 0 0 0 0 0 1 1 1
0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 0 0 0 1 0 1 back ,leg 1 1 1
0 1 0 0 1 1 0 0 1 arms,legs 1 1 1
1 0 0 0 0 0 0 0 0 0 1 1 1
1 1 0 0 1 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 1 1 1
1 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 0 1 0
1 1 0 1 0 1 1 0 0 0 1 0 1
1 0 0 0 0 0 0 0 0 0 1 1 0
1 1 1 0 1 0 1 0 0 0 1 1 0
1 0 0 0 0 0 0 0 0 0 0 1 0
1 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0 0 0 1 0 0
1 0 0 0 0 0 0 0 0 0 1 1 0
1 0 0 0 0 0 1 0 0 0 0 0 0
1 1 0 0 0 0 1 0 1 0 0 1 0
1 1 0 1 1 0 1 0 1 legs,arms,back 1 1 1
1 0 0 0 0 0 0 0 0 0 1 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 1 0 0 1 0 1 arms,legs 1 0 0
1 1 0 0 0 1 0 0 1 0 1 0 0
1 0 0 0 0 0 0 0 0 0 1 1 0
0 0 0 0 0 0 0 0 0 0 0 0 0
1 1 0 1 0 1 1 0 1 body 1 1 1
1 0 0 0 0 0 0 0 0 0 0 0 0
Coryza Sleep/Lethargy Last Episode of fever Temp <39 Temp >39 Paloor Face flush Conj.Injection Lyphadenopathy Systemicexamination TC DC-N DC-L DC - E PCV
0 1 0 1 1 1 1 1 6500 72 25 3 44
1 1 1 1 1 1 4500 64 36 42
1 1 0 1 0 0 0 0 0 10000 84 16 36
1 1 0 1 0 0 1 1 0 2500 70 25 5 48
1 1 1 1 0 0 0 0 0 8000 74 26 38
0 0 0 1 0 0 1 0 0 2000 60 27 13 42
0 0 0 1 0 1 1 1 0 6500 56 44 36
0 0 0 1 0 0 1 0 0 9000 62 34 4 38
0 0 0 1 0 0 0 0 0 8000 60 30 10 34
0 1 0 1 0 0 0 0 0 2500 58 38 4 34
1 1 0 1 1 0 0 0 0 0 4000 50 49 1 42
1 1 1 1 1 1 1 1 1 0 9400 76 20 4 50
1 1 0 1 0 0 1 1 0 4000 42 56 2 37
1 1 0 1 0 1 1 0 0 11000 54 37 9 40
1 0 0 1 1 0 0 0 0 3600 83 42 4 56
1 1 1 1 1 0 0 0 0 3200 57 33 10 26
1 1 0 1 0 0 0 0 0 4400 50 50 38
1 0 0 1 0 0 0 0 0 7300 82 15 3 36
0 1 0 1 0 0 0 0 0 4000 40 50 10 43
0 1 0 1 0 0 0 1 0 4500 40 50 10 43
1 1 1 1 1 1 0 8000 53 37 10 43
0 1 0 1 0 1 1 1 0 3000 44 46 0 48
0 0 1 0 0 0 1 0 4800 57 40 3 44
1 1 0 1 0 0 1 1 0 5200 60 30 10 49
1 0 1 0 1 0 1 0 4000 30 70 0 36
1 1 1 0 0 0 0 0 3000 64 35 1 35
1 1 0 1 0 0 1 0 0 3000 60 30 10 46
1 1 0 1 0 0 0 0 spleen 4500 45 50 5 46
0 0 1 1 0 0 0 0 0 7000 77 25 3 38
1 1 0 1 0 0 0 0 0 6300 73 27 0 30
0 1 0 1 1 1 1 1 0 4100 56 44 36
0 0 0 0 1 0 0 1 0 0 12000 70 24 6 42
1 1 1 1 0 1 1 1 0 12800 60 30 5 40
1 1 1 1 1 0 1 0 0 9600 85 15 0 40
1 0 0 1 0 0 0 0 0 5400 60 35 5 38
1 1 1 1 0 0 0 0 0 5600 65 33 2 40
0 1 1 0 0 0 1 1 0 0 3900 50 40 10 44
0 1 0 1 0 0 1 0 0 8000 68 30 2 38
1 1 0 1 1 1 1 1 0 12000 67 25 8 52
1 1 0 0 1 0 0 0 0 0 4400 60 40 0 42
0 0 0 1 0 0 0 0 0 6300 68 31 1 40
0 0 1 1 0 1 1 0 0 2900 56 44 0 48
1 1 0 1 0 0 1 0 0 7100 60 40 0 40
1 1 0 1 0 0 1 1 0 5500 80 20 0 42
0 1 1 1 0 1 1 1 0 6500 64 36 0 48
1 1 1 1 1 1 1 1 0 4000 48 52 0 36
1 1 0 1 0 0 1 0 0 13000 84 11 0 28
1 1 0 1 1 0 0 0 0 8900 70 26 4 38
0 1 0 0 0 0 0 0 0 4000 54 42 4 30
1 1 0 1 0 0 1 0 0 6800 57 43 0 37
1 0 1 1 1 0 0 1 1 0 5700 80 20 0 36
0 0 0 1 1 1 1 1 0 8000 60 37 3 32
1 0 0 1 0 0 1 1 0 2900 76 24 0 44
1 0 1 1 0 0 0 0 0 4000 71 29 0 36
1 1 1 1 0 1 1 1 0 3400 25 45 20 50
1 0 0 1 1 0 0 0 0 0 14000 70 27 3 38
1 1 1 1 1 1 1 0 hepa 2800 38 42 20 38
1 0 0 1 0 0 0 0 0 5600 70 24 6 36
1 1 1 1 1 1 1 1 0 13000 60 26 14 44
1 1 0 1 1 1 1 0 hepa 4200 63 37 0 36
0 0 0 0 1 0 1 0 0 0 5700 52 40 8 36
0 0 0 0 1 0 0 0 0 0 3600 58 35 11 40
1 0 0 1 0 0 1 0 0 2600 54 40 6 38
0 1 0 1 0 0 1 1 0 0 3600 60 30 10 50
0 1 0 0 1 0 0 0 0 0 4200 74 25 1 48
0 0 0 0 1 0 0 0 0 0 3300 62 38 0 48
1 1 1 1 0 1 0 0 0 11000 62 38 0 48
1 1 0 1 0 0 1 0 0 spleen 5700 78 11 11 45
0 0 1 1 0 0 1 0 0 2800 60 38 2 35
0 0 0 0 1 0 0 0 1 0 3200 60 36 4 38
0 0 0 0 1 0 0 0 0 0 6400 64 30 6 40
0 0 0 1 0 0 0 0 1 0 4000 60 38 2 38
1 0 0 0 1 0 1 0 0 0 5100 66 30 4 36
0 0 0 1 0 1 0 1 0 3000 50 30 10 46
0 1 1 1 0 0 0 0 0 4300 56 44 0 32
0 1 1 1 0 0 1 1 spleen 4600 53 43 9 37
0 1 1 1 1 0 1 1 1 hepa 4800 55 40 5 32
1 1 0 1 0 0 0 0 0 0 4000 50 37 3 38
1 0 0 1 0 0 1 0 0 3200 74 20 6 41
0 1 0 1 0 0 0 0 psychiatric behaviour 3600 72 27 1 36
0 1 0 1 1 1 1 1 0 11000 50 45 4 55
0 0 0 1 0 0 0 0 0 0 6200 66 32 2 40
0 0 0 1 0 0 0 0 0 0 4000 70 24 6 36
0 0 0 1 0 0 0 0 0 0 4100 50 48 2 40
0 1 0 1 0 0 1 1 0 4500 45 50 5 38
0 1 0 1 0 1 1 0 hepa 5200 57 26 17 43
0 0 0 1 0 0 0 0 0 7200 70 30 0 40
0 0 0 0 1 0 0 0 1 0 10000 75 23 2 36
1 0 1 1 0 0 1 0 0 4800 65 30 5 36
0 0 0 0 1 0 0 0 0 0 3600 55 35 10 40
1 0 0 0 0 0 0 0 0 2800 39 41 20 40
1 1 0 1 0 0 1 0 0 3600 48 42 10 42
1 0 0 1 0 0 0 0 0 8000 60 30 10 37
1 0 0 0 1 0 0 1 1 0 9200 62 34 4 38
0 1 0 1 0 0 0 1 0 11000 54 37 9 40
1 0 0 0 1 0 0 0 1 0 4000 70 28 2 42
1 0 0 1 0 0 0 0 0 0 6300 64 35 1 42
1 1 0 0 1 0 1 0 0 0 7200 90 10 0 46
0 1 0 1 0 0 1 1 1 0 3200 70 23 7 51
0 1 0 0 1 0 0 0 0 0 4000 50 49 1 40
1 0 0 1 0 0 0 0 1 0 3200 72 21 7 43
1 1 1 1 0 0 0 1 1 0 2700 60 30 10 46
1 1 0 0 1 0 0 1 0 0 12000 84 11 5 48
1 1 1 0 1 0 1 0 0 0 4000 71 29 0 36
0 1 0 1 0 0 0 0 0 0 10000 80 20 0 49
0 0 0 0 1 0 1 0 0 0 6300 72 28 0 46
1 1 0 1 0 0 1 0 0 12300 54 37 9 40
0 0 0 0 1 0 0 0 0 0 5600 70 24 6 38
0 0 0 0 1 0 0 1 0 0 9000 83 15 2 41
1 0 1 1 1 0 0 1 1 0 6800 57 43 0 37
1 1 0 1 1 0 0 0 0 0 4000 50 49 1 42
0 0 0 0 1 0 0 1 0 0 12000 70 24 6 42
0 0 0 1 0 0 0 0 0 0 4000 70 24 6 36
0 1 0 1 0 0 1 1 0 0 3600 60 30 10 50
0 1 0 1 0 0 0 0 0 0 10000 80 20 0 49
1 0 0 1 1 0 0 0 0 0 14000 70 27 3 38
1 1 1 1 0 1 0 0 0 11000 62 38 0 48
o   r 0 0 1 0 0 1 0 0 6500 56 44 36
0 1 0 0 0 0 0 0 0 4000 54 42 4 30
0 1 0 1 0 0 0 0 psychiatric behaviour 3600 72 27 1 36
1 1 1 1 1 1 0 8000 53 37 10 43
0 0 0 0 1 0 0 1 0 0 12000 70 24 6 42
HB Platelet BT CT Sugar Urea Crea LFT S.Bil SGOT SGPT SAP T.Protein S.Alb IgM IgG CXR USG Abdomen Hepato/Spleen Ascites Pleural Eff Hypotension
14 12000 n n 140 42 1 ab 0.7 232 62 125 5.5 2.8 p n n gall bladder wall hep;spleen 1 b pe 1
13 55000 n n 68 35 0.9 ab 1.1 129 94 59 5.7 3.4 p p n gall bladder wall spleen 1 rt pe 0
11 300000 n n 108 28 0.9 n 1 36 26 93 5.6 3.5 n p n 0 0 0 0 0
15 40000 n n 108 26 0.8 ab 0.9 148 160 154 5.8 3.4 p p n rt pe 0 0 rt pe 0
14 145000 n n 138 18 0.8 n 1 76 39 47 5.9 4 p p copd 0 0 0 0 0
14 84000 n n 100 26 0.6 ab 1.1 55 49 62 5.5 3.6 n p n 0 0 0 0 0
11 130000 n n 72 21 1.1 n 1 36 40 67 6.1 3.4 p n n 0 0 0 0 0
13.3 60000 n n 96 28 0.9 n 0.8 32 30 66 6 3.2 n p n 1 0 1 bl pe 1
11 280000 n n 72 20 0.8 n 1 36 39 58 5.6 3.6 n p n 0 0 0 0 0
11 160000 n n 76 16 0.9 n 0.8 40 38 88 5.8 3.6 p p n 0 0 0 0 0
13.2 210000 n n 80 20 0.7 n 1.1 46 33 76 5.5 3.7 n p n 1 hep;spleen 0 0 0
15 15000 n n 125 26 0.9 ab 1.4 156 98 110 5.9 3.4 p p rt pe 1 0 1 b pe 0
12 75000 n n 114 32 0.82 ab 1 55 36 112 5.8 3.6 p p n 1 spleen 0 0 0
13 55000 n n 124 42 1 n 1.1 36 32 68 5.8 4 p p rt pe rt pe 0 rt pe 0
18 65000 n n 128 31 1.2 ab 1 47 55 60 6.4 4 p p n 0 0 0 0 0
7 35000 n n 112 32 1 ab o.9 196 148 140 6.3 4.2 p n n 0 0 1 1 1
11 47000 n n 98 34 1 n 0.8 36 34 102 6 3.8 p n n 0 n 0 0 0
12 180000 n n 121 32 0.98 n 1 43 36 84 5.8 4 p p n 1 spleen 0 0 0
14 120000 n n 118 34 1.1 n 0.9 38 43 87 6 3.9 p p n 0 0 0 0 0
13 50000 n n 96 32 1.1 ab 1 195 160 78 5.6 3 p p n 1 0 1 0 0
14 18000 n n 90 20 0.9 ab 1.2 240 153 115 6.1 4 p p n 1 0 1 rt pe 1
17.2 40000 n n 96 26 0.8 ab 1.1 192 121 122 5 3 p p n 1 hep 1 rt pe 0
14 154000 n n 56 21 0.8 n 1 46 25 128 6.7 3.8 p p n 0 0 0 0 0
16.4 25000 n n 123 34 1 ab 1 183 128 71 6.2 3.6 p p rt pe gall bladder wall spleen 1 b pe 0
11 249000 n n 132 41 1 n 1 48 32 121 6.3 3.5 n p n 0 0 0 0 0
10 156000 n n 141 38 0.8 n 0.9 38 32 86 5.8 3.6 p p n 0 0 0 0 0
14 150000 n n 121 35 1 n 0.8 42 36 78 6.2 4 p 0 n 0 0 0 0 0
14 110000 n n 75 21 0.8 n 1 46 36 78 5.8 3.6 p 0 n 1 spleen 0 0 0
9.8 127000 n n 146 32 0.9 n 1.1 42 37 96 6 3.8 p p n 0 0 0 0 0
12 35000 n n 113 36 1 n 1 36 38 78 5.8 3.8 p 0 n 0 0 0 0 0
11 83000 n n 72 36 0.8 ab 1 83 76 112 5.8 3.4 p p n 1 0 1 lt pe 0
13 280000 n n 122 40 1 ab 1.1 88 45 104 6 4 p 0 n 1 hep 0 0 0
14 34000 n n 100 36 1 ab 1 116 123 102 6.1 3.9 0 p n 1 hep:spleen 1 rt pe 0
13 50000 n n 84 36 0.8 n 1.1 38 41 83 5.7 3.9 p p n 1 0 0 rt pe 0
10 67000 n n 100 34 0.7 ab 0.8 148 122 98 6 3.5 p p n gall bladder wall hep 1 0 0
13 54000 n n 73 28 0.9 n 1 28 24 64 5.8 3.7 p p n 1 0 1 bl pe 0
14 80000 n n 100 17 0.8 ab 0.8 270 127 122 5.6 3.6 p 0 n 1 0 1 lt pe 0
13 220000 n n 87 21 1 n 1 34 36 112 6.7 3.6 p p n 0 0 0 0 0
16 29000 1 n 120 32 0.8 ab o.8 112 94 110 6.4 3.4 p p n 1 spleen 1 rt pe 0
13 180000 n n 113 28 0.9 ab 1 117 116 68 7 3.7 p p n 0 0 0 0 0
13 177000 n n 98 23 0.9 n 0.8 35 32 69 5 3.2 0 p n 0 0 0 0 0
13 80000 n n 112 32 0.5 ab 0.9 92 42 88 5.6 3.4 p p n 1 0 1 lt pe 1
13 90000 n n 103 28 0.9 n o.8 43 35 110 6.1 3.6 p 0 n 0 0 0 0 0
12 220000 n n 98 28 0.8 n 1 22 16 84 5.6 3 p p n 0 0 0 0 0
12 88000 1 n 100 26 1 ab 1.1 92 82 112 6 3.6 p p n 1 0 1 rt pe 0
12 44000 n n 102 28 0.8 ab 1 52 48 105 5.4 3.2 p p n 1 0 1 b pe 1
10 310000 n n 98 32 0.9 n 1.1 38 32 96 6 3.5 p p n 0 0 0 0 0
12 420000 n n 103 31 1 n 1 24 19 101 5.8 3.2 p p n 0 0 0 0 0
13 110000 n n 112 30 1 n 0.8 30 28 98 5.9 3.5 p p n 0 0 0 0 0
13 150000 n n 102 32 1 n 1 30 26 112 5.6 3 p 0 n 0 0 0 0 0
12 120000 n n 102 30 0.8 n 0.9 28 30 95 6 3 p p n 0 0 0 0 0
11 180000 n n 101 28 0.7 n 1 32 28 88 5.6 3.2 p p n 0 0 0 0 0
13 147000 n n 98 23 1 n 1 38 19 61 5.8 3.2 p p n 0 0 0 0 0
12 105000 n n 100 21 0.9 n 0.9 32 28 87 5.4 3 p 0 n 0 0 0 0 0
14 27000 1 n 98 28 0.9 ab 0.9 294 130 123 5 3.4 p p n 1 spleen,GB 1 rt pe 0
13 220000 n n 96 30 1 n 0.9 36 30 112 5.6 3.2 p p n 0 0 0 0 0
13 22000 n n 100 32 0,9 ab 1 106 98 110 5.6 3.4 p p n 1 hep 1 lt pe 0
12.8 320000 n n 99 21 0.8 n 0.8 34 25 78 6 3 p p n 0 0 0 0 0
14 30000 n n 80 23 0.9 ab 0.9 128 118 106 5.4 3.5 p p n 1 gb 1 b pe 1
14 42000 n n 99 21 1 ab 1.1 130 120 115 5.6 3.5 p p n 1 gb 1 rt pe 0
12 180000 n n 98 25 0.7 n 1 32 28 98 5.6 3.4 0 p n 0 0 0 0 0
12 140000 n n 74 29 0.6 n 0.8 28 25 87 5.4 3.4 0 p n 0 0 0 0 0
13 140000 n n 78 6 1 n 0.8 32 28 98 5.8 3.5 0 p n 0 0 0 0 0
15 62000 n n 98 38 0.7 ab 0.9 182 170 110 5 3.4 p p n 1 0 1 rt pe 0
14 114000 n n 102 34 1 n 0.8 34 32 98 5.8 3.5 p p n 1 spleen 0 0 0
15 60000 n n 80 19 1 ab o.8 74 41 78 5.5 3.3 p 0 n 1 0 1 lt pe 0
13 28000 n n 92 18 0.7 ab 1 130 140 112 5.8 3.4 p p n 1 0 1 rt pe 0
14 45000 n n 92 32 0.7 ab 1 110 106 130 6.2 3.5 p p n 0 0 0 0 1
10 71000 n n 83 26 0.7 n 0.8 32 23 89 5.3 3.8 p p n 1 spleen 0 0 0
11 120000 n n 59 23 0.8 n 1 34 32 98 5.4 3 0 p n 0 0 0 0 0
14 101000 n n 64 36 0.8 n 1 38 28 108 5.8 3.2 p p n 0 0 0 0 0
12 109000 n n 87 23 0.9 n 1 32 23 56 5.4 3.2 p 0 n 0 0 0 0 0
11 180000 n n 96 40 0.9 n 0.7 28 22 94 5.8 3.2 p 0 n 0 0 0 0 0
13 80000 n n 98 31 1 n 1 178 150 110 5.8 3.6 p p n 1 0 1 rt pe 0
11 80000 n n 85 40 1 n 0.8 28 34 112 5.4 3.2 0 p n gall bladder wall 0 1 rt pe 0
11 83000 n n 97 23 0.7 n o.8 48 40 84 5.9 3.2 p p n 1 spleen 1 lt pe 0
10 59000 n n 66 23 0.5 ab 0.8 126 118 178 6.1 4 p 0 n 1 hep,spleen 1 rt pe 0
11 80000 n n 87 22 0.7 ab 1 89 44 87 5.4 3 p 0 n 1 spleen 1 rt pe 1
14 80000 n n 98 24 0.8 n 1 26 19 57 6.3 3.5 p p n 0 0 0 0 0
13 130000 n n 96 28 0.9 n 0.9 42 34 89 5.6 3.5 p 0 n 0 0 0 0 0
15 10000 1 1 55 41 1 ab 1 112 100 78 5 2.2 0 p n 1 0 1 rt pe 1,shock
14 66000 n n 68 32 1 ab 0.9 72 36 100 5.6 3.4 p p n 1 0 1 0 0
11 10000 n n 86 32 0.9 n 1 43 34 98 5.4 3.5 p p n 1 0 1 0 0
13 134000 n n 84 34 1 n 0.8 43 45 100 5.5 3.4 p p n 0 0 0 0 0
12 26000 n n 77 29 0.9 ab 1 256 143 112 6 3.2 p p n 1 0 1 b pe 0
13 12000 n n 96 20 0.8 n 0.8 34 32 98 5.4 3.2 p p n 1 hep 0 bpe 1,shock
12 210000 n n 87 23 0.9 n 0.5 32 26 89 5.9 3.5 0 p n 0 0 0 0 0
11 189000 n n 89 32 0.8 n 0.6 25 23 87 5.7 3.4 0 p n 0 0 0 0 0
12 110000 n n 69 43 1 n 0.9 23 22 98 5.3 3.3 p p n 0 0 0 0 0
14 112000 n n 78 32 1 n 0.8 24 34 78 5.4 3.2 p 0 n 0 0 0 0 0
12 60000 n n 98 23 0.8 n 1 28 24 86 5.3 3 p 0 n 0 0 0 0 0
13 40000 n n 84 23 0.6 n 0.8 32 28 78 5.9 3.5 p 0 n 1 0 1 rt pe 0
11 280000 n n 78 25 0.8 n 0.9 43 34 98 6 3.7 p 0 n 0 0 0 0 0
12 256000 n n 78 34 1 n 0.5 32 24 96 5.7 3.4 p p n 0 0 0 0 0
13 56000 n n 160 43 1 n 1 44 32 55 5.3 3.2 p p n 1 0 1 rt pe 0
12 249000 n n 126 34 1 n 0.4 33 26 87 6 3.8 0 p n 0 0 0 0 0
11 156000 n n 129 19 0.8 n 0.6 48 42 89 5.6 3.4 0 p n 0 0 0 0 0
12 90000 n n 112 32 0.8 n 0.7 32 25 89 5.4 3.2 p p n 1 0 1 rt pe 0
17.2 40000 n n 96 29 0.4 ab 1 192 121 112 5.3 3 p p n 1 hep;spleen 1 0 1
12 120000 n n 98 32 0.6 n 0.7 25 22 78 5.4 3.4 p p n 1 hep;spleen 0 0 0
12 40000 n n 96 32 0.8 n 0.8 142 106 68 6 3.6 p p n 1 0 1 rt pe 0
14 158000 n n 139 34 1 n 0.6 28 23 87 5.4 3.9 p p n 0 0 0 0 0
14 340000 n n 154 36 0.8 n 0.4 28 23 89 5.8 3.6 p p n 0 0 0 0 0
11 105000 n n 112 32 0.9 n 0.8 34 25 88 5.8 3.8 p 0 n 0 0 0 0 0
13 28000 n n 76 34 0.8 n 0.9 110 103 88 6 3.4 p 0 n 1 0 1 lt pe 0
12 35000 n n 113 32 0.7 n 0.8 24 22 98 5.4 3.6 p p n 0 0 0 0 0
15 55000 n n 80 23 0.8 n 0.8 36 26 88 5.9 3.5 p p n 1 0 1 rt pe 0
13 320000 n n 85 34 0.5 n 0.5 29 24 79 5.8 3,2 p 0 n 0 0 0 0 0
14 118000 n n 112 32 0.6 n 0.5 32 25 88 5.6 3.4 0 p n 0 0 0 0 0
13 150000 n n 102 32 1 n 1 30 26 112 5.6 3 p 0 n 0 0 0 0 0
13.2 210000 n n 80 20 0.7 n 1.1 46 33 76 5.5 3.7 n p n 1 hep;spleen 0 0 0
13 280000 n n 122 40 1 ab 1.1 88 45 104 6 4 p 0 n 1 hep 0 0 0
11 10000 n n 86 32 0.9 n 1 43 34 98 5.4 3.5 p p n 1 0 0 rt pe 0
15 62000 n n 98 38 0.7 ab 0.9 182 170 110 5 3.4 p p n 1 0 1 rt pe 0
13 28000 n n 76 34 0.8 n 0.9 110 103 88 6 3.4 p 0 n 0 0 0 0 0
13 220000 n n 96 30 1 n 0.9 36 30 112 5.6 3.2 p p n 0 0 0 0 0
13 28000 n n 92 18 0.7 ab 1 130 140 112 5.8 3.4 p p n 1 0 1 rt pe 0
11 130000 n n 72 21 1.1 n 1 36 40 67 6.1 3.4 p n n 1 0 1 lt pe 0
13 110000 n n 112 30 1 n 0.8 30 28 98 5.9 3.5 p p n 0 0 0 0 0
13 130000 n n 96 28 0.9 n 0.9 42 34 89 5.6 3.5 p 0 n 0 0 0 0 0
14 18000 n n 90 20 0.9 ab 1.2 240 153 115 6.1 4 p p n 1 0 1 rt pe 1
13 280000 n n 122 40 1 ab 1.1 88 45 104 6 4 p 0 n 1 hep 0 0 0
tachycardia ↑HCT Plasma leak Fever Thrombocytopenia Plasma leak Hges Bp Infection Type Dengue Blood trans Platelet trans. Comments 
1 1 1 1 1 1 1 1 1 DHF-3 0 0 recoverd in 3days 
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 antenatal 6months
0 1 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 1 0 0 0 1 DF,T 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
1 0 1 1 1 1 1 1 2 DHF-3 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
1 1 1 1 1 1 1 0 2 DHF-2 0 1 4uplatelet,3uffp transfused
0 0 0 1 1 0 0 0 2 DF,T 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 0 0
1 0 1 1 1 1 1 1 1 DHF-3 1 1
0 0 0 1 0 0 0 0 1 DF,T 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-1 0 0 0
1 0 1 1 1 1 1 1 2 DHF-3 5unit platelet
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 0
0 0 0 1 0 0 0 0 2 DF 0 0
0 0 0 1 0 0 0 0 2 DF 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0
0 0 1 1 1 1 1 0 2 DHF-1 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 1 1 1 1 1 0 1 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 1 4units platelets 
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 Df 0 0
1 1 1 1 1 1 1 1 2 DHF-3 0 in fluid mangaement 
0 0 o 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
1 0 1 1 1 1 1 1 2 DHF-3 4ffp, 2 bllod 2platelet 1u blood,2 uplatelet
0 0 0 1 0 0 0 0 2 DF,encheplalitis
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 4plate 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
1 0 1 1 1 1 1 1 2 DSS 0 4platelet ivfliud
1 0 1 1 1 1 1 1 2 DHF-3 0 0 iv fliud
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 Df 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
1 0 1 1 1 1 1 1 2 DHF-2 0 0 0
0 0 0 1 1 0 0 0 2 DF,T 0 0 0
0 0 0 1 0 0 0 0 2 DF,encheplalitis o o recovered 2days
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 1 1 1 1 1 0 1 DHF-2 0 0 0
1 1 1 1 1 0 0 0 1 DF,T 0 0 0
0 0 0 1 1 0 0 0 2 DF,T 0 0 0
0 0 0 1 0 0 0 0 1 DF,encheplalitis 0 0 encephalopathy
1 1 1 1 1 1 1 1 2 DSS,Death 4ffp, 2 bllod 8platelet irrestable shoick
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 1 1 1 1 1 0 2 DHF-1 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
1 0 1 1 1 1 1 1 2 DSS 0 4platelet iv fluid reco in 1day
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 Df 0 0 0
0 0 0 1 1 0 0 0 1 DF,T 0 0 0
0 0 1 1 1 1 1 0 1 DHF-2 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
1 1 1 1 1 1 1 1 2 DHF-3 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 1 1 1 0 1 DHF-2 0 0 0
0 0 0 1 1 0 0 0 2 DF,T 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-1 0 0 0
0 1 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 1 0 0 0 1 DF,T 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 1 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 1 1 1 0 2 DHF-2 0 0 0
0 0 0 1 0 0 0 0 2 DF 0 0 0
0 0 0 1 0 0 0 0 1 DF 0 0 0
1 0 1 1 1 1 1 1 2 DHF-3 5unit platelet
0 0 0 1 0 0 0 0 1 DF 0 0 0
